Oligonucleotides for modulating Tau expression

By designing antisense oligonucleotide-targeted MAPT transcripts, using gap body design and sugar-modified nucleotide technology, the problem of difficulty in reducing Tau protein expression in the prior art is solved, effective inhibition of Tau protein expression is achieved, and the potential for treating neurodegenerative diseases is possible.

CN120137967APending Publication Date: 2025-06-13F HOFFMANN LA ROCHE & CO AG
View PDF 38 Cites 0 Cited by

Patent Information

Application Number
CN202510098340.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-08-31
Filing Date
2019-07-03
Publication Date
2025-06-13

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reduce the expression of Tau protein, resulting in the treatment of related neurodegenerative diseases.

Method used

Tau protein expression is inhibited by designing antisense oligonucleotides of 10 to 30 nucleotides in length, targeting specific regions in the MAPT transcripts, using gap body design and sugar-modified nucleotide technology.

Benefits of technology

It has achieved the reduction of Tau protein expression in vivo and in vitro, and has potential effects on the treatment of diseases such as Alzheimer's disease and Tau abnormal deposition lesions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120137967A_ABST
    Figure CN120137967A_ABST
Patent Text Reader

Abstract

The present invention relates to antisense oligonucleotides capable of modulating the expression of Tau in a target cell. The oligonucleotide lines hybridize to the MAPT mRNA. The present invention further relates to conjugates of the oligonucleotides, and pharmaceutical compositions and methods for the treatment of a Tau aberrant deposition lesion (Tauopathy), Alzheimer's disease (AD), frontotemporal dementia (FTD), FTDP-17, progressive ocular nuclear paralysis (PSP), chronic traumatic brain lesion (CTE), corticobasal nuclear degeneration (CBD), epilepsy, a Display syndrome, depression, a seizure disorder (disorder of epileptic seizure), and a movement disorder (disorder of movement).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the patent application with the application number 201980044785.3 and the invention title "Oligonucleotides for Modulating Tau Expression". Technical Field

[0002] The present invention relates to oligonucleotides (oligomers) that are complementary to microtubule-associated protein Tau (MAPT) transcripts and result in reduced expression of Tau. A reduction in MAPT transcript and / or Tau protein expression is beneficial for a range of medical conditions, such as Tauopathies, Alzheimer's disease, frontotemporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorder, and movement disorder. Background Art

[0003] Tau is a microtubule-associated protein (MAP) that interacts with tubulin and is involved in microtubule assembly and stabilization. Microtubules are key structural components of the cellular cytoskeleton and are involved in various cellular processes, including mitosis, cytokinesis, and vesicle transport. Tau protein is present in multiple cell and tissue types but is particularly abundant in neurons, where it plays a key role in regulating axonal transport and function.

[0004] Altered Tau expression levels and / or function contribute to the pathophysiology of various neurodegenerative disorders. For example, misfolded and hyperphosphorylated Tau aggregates have been found in neurofibrillary inclusions associated with and related to Alzheimer's disease (AD) and Tauopathies such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD) and FTD with Parkinsonism linked to chromosome 17 (FTDP-17), Pick's disease (PiD), argyrophilic grain disease (AGD), tangle-predominant senile dementia (TPSD), primary age-related Tauopathy (PART), Down syndrome, and Guamanian lytico-bodig disease. Upregulation of pathological Tau is associated with infantile Tauopathies, including hemimegalencephaly (HME), tuberous sclerosis complex; focal cortical dysplasia type 2b; and ganglioglioma. In addition, abnormal Tau expression and / or function may also be associated with other diseases, such as Hallervorden-Spatz syndrome, also known as neurodegeneration with brain iron accumulation type 1 (NBIA1), gangliocytoma, and subacute sclerosing panencephalitis. Tau may also play a role in seizure disorders (e.g., epilepsy), network dysfunction (e.g., depression), and movement disorders (e.g., Parkinson's disease).

[0005] Antisense molecules and siRNA molecules that can reduce Tau protein levels by targeting MAPT pre-mRNA or mRNA transcripts have been described, for example, in De Vos et al., 2013 Journal of Neuroscience Vol 33 pp 12887, WO2013 / 148260, WO2014 / 153236, WO2015 / 010135, WO2016 / 126995, WO2016 / 151523, WO2017 / 09679, and WO2018 / 064593. Antisense oligonucleotides that can induce splicing modulation of MAPT transcripts have also been described in Sud et al., 2014 Mol Ther Nucl Acid 3 e180 and WO2016 / 019063.

[0006] Tau-related disorders such as AD are the most common cause of dementia in the elderly, and there is a great need for potent and effective agents for treating AD and related neurodegenerative diseases, including Tauopathies, seizure disorders, and movement disorders.

[0007] Objectives of the Invention

[0008] The present invention provides antisense oligonucleotides that can reduce Tau both in vivo and in vitro. The present invention proposes three specific target regions in the pre-mRNA of MAPT located in intron 1 or 2 of the human MAPT pre-mRNA, which can be targeted by antisense oligonucleotides to produce effective Tau inhibition. Specifically, for reducing Tau, it is advantageous to target positions 12051 to 12111, 39562 to 39593, and / or 72837 to 72940 of SEQ ID NO: 1. The present invention also provides effective antisense oligonucleotide sequences and compounds capable of reducing Tau, as well as their use in treating diseases or disorders such as neurodegenerative diseases, including Tau deposition disorders, Alzheimer's disease, FTDP-17, seizure disorders, and movement disorders. Summary of the Invention

[0009] The present invention relates to oligonucleotides that target Tau-encoding nucleic acids and are capable of regulating Tau expression, and the use of such oligonucleotides to treat or prevent diseases related to Tau function.

[0010] Thus, in a first aspect, the present invention provides an oligonucleotide having a length of 10 to 30 nucleotides, which comprises a continuous nucleotide sequence having a length of at least 10 nucleotides and having at least 90% complementarity with a specific region of MAPT represented by SEQ ID NOs: 3, 4, and 5.

[0011] The oligonucleotide can be an antisense oligonucleotide, preferably having a gapmer design. Preferably, the oligonucleotide is capable of inhibiting Tau expression by cleavage of the target nucleic acid. The cleavage is preferably achieved via nuclease recruitment.

[0012] In yet another aspect, the present invention provides a pharmaceutical composition comprising the oligonucleotide of the present invention and a pharmaceutically acceptable diluent, carrier, salt, and / or adjuvant.

[0013] In yet another aspect, the present invention provides a method, which is an in vivo or in vitro method for regulating Tau expression in target cells expressing Tau by administering an effective amount of the oligonucleotide or composition of the present invention.

[0014] In a further aspect, the present invention provides a method for treating or preventing a disease, disorder, or dysfunction related to the in vivo activity of Tau, the method comprising administering a therapeutically or prophylactically effective amount of the oligonucleotide of the present invention to a subject suffering from or susceptible to the disease, disorder, or dysfunction.

[0015] In a further aspect, the oligonucleotides or compositions of the invention are used for treating or preventing Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or FTDP-17. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 : Screening results from an oligonucleotide library (Example 1) covering all intronic regions on MAPT. Each point represents an oligonucleotide compound, the x-axis depicts its position on the MAPT transcript, and the y-axis shows the remaining amount of MAPT mRNA compared to the control group (low amounts correspond to a large reduction in MAPT). A, B, and C represent three regions on the MAPT transcript that were selected as target regions for additional oligonucleotide compounds.

[0017] Figure 2 : Compound 9_103 (sequence of nucleobases shown in SEQ ID NO 9)

[0018] Figure 3 : Compound 9_104 (sequence of nucleobases shown in SEQ ID NO 9)

[0019] Figure 4 : Compound 11_1 (sequence of nucleobases shown in SEQ ID NO 11)

[0020] Figure 5 : Compound 49_38 (sequence of nucleobases shown in SEQ ID NO 49)

[0021] Figure 6 : Compound 49_189 (sequence of nucleobases shown in SEQ ID NO 49)

[0022] Figure 2 , Figure 3 , Figure 4 , Figure 5 and Figure 6 The compounds shown in are depicted in their protonated form, i.e., the sulfur atom on the phosphorothioate bond is protonated; it should be understood that the presence of the proton will depend on the environmental acidity of the molecule and the presence of selective cations (e.g., when the oligonucleotide is in the form of a salt). Protonated phosphorothioates exist in a tautomeric form.

[0023]

DEFINITIONS

[0024] Oligonucleotide

[0025] As used herein, the term "oligonucleotide" is defined as a molecule containing two or more covalently linked nucleosides, as is known to those of ordinary skill in the art. These covalently linked nucleosides may also be referred to as nucleic acid molecules or oligomers. Oligonucleotides are typically made in the laboratory, first synthesized by solid-phase chemistry and then purified and isolated. When referring to the sequence of an oligonucleotide, it refers to the sequence or order of the nucleobase portions of covalently linked nucleotides or nucleosides or their modifications. The oligonucleotides of the present invention are artificial and chemically synthesized, and are usually purified or isolated. The oligonucleotides of the present invention may contain one or more modified nucleosides or nucleotides, such as 2'-sugar modified nucleosides.

[0026] Antisense oligonucleotide

[0027] As used herein, the term "antisense oligonucleotide" is defined as an oligonucleotide capable of regulating the expression of a target gene by hybridizing to a target nucleic acid, specifically to a continuous sequence on the target nucleic acid. Antisense oligonucleotides are not substantially double-stranded and are thus not siRNA or shRNA. The antisense oligonucleotides of the present invention are preferably single-stranded. It should be understood that as long as the degree of self-complementarity within or between sequences across the entire length of the oligonucleotide is less than 50%, the single-stranded oligonucleotides of the present invention can form hairpin or intermolecular duplex structures (duplexes between two molecules of the same oligonucleotide).

[0028] Advantageously, the single-stranded antisense oligonucleotides of the present invention do not contain RNA nucleosides, as this would reduce nuclease resistance.

[0029] Advantageously, the antisense oligonucleotides of the present invention contain one or more modified nucleosides or nucleotides, such as 2'-sugar modified nucleosides. In addition, advantageously, the unmodified nucleosides are DNA nucleosides.

[0030] Continuous nucleotide sequence

[0031] The term "continuous nucleotide sequence" means the region of an oligonucleotide that is complementary to a target nucleic acid or target sequence. In this context, this term may be used interchangeably with "continuous nucleobase sequence" and "oligonucleotide motif sequence". In certain embodiments, all of the nucleotides of the oligonucleotide constitute the continuous nucleotide sequence. In certain embodiments, the oligonucleotide contains a continuous nucleotide sequence, such as an F-G-F' nick region, and may optionally contain other nucleotides, such as a nucleotide linker region that can be used to attach functional groups to the continuous nucleotide sequence. The nucleotide linker region may or may not be complementary to the target nucleic acid. It should be understood that the continuous nucleotide sequence of the oligonucleotide cannot be longer than the oligonucleotide itself, and the oligonucleotide cannot be shorter than the continuous nucleotide sequence.

[0032] Nucleotide

[0033] Nucleotides are the building blocks of oligonucleotides and polynucleotides and include both naturally occurring and non-naturally occurring nucleotides in the present invention. In essence, nucleotides such as DNA and RNA nucleotides contain a ribose moiety, a nucleobase moiety, and one or more phosphate groups (no phosphate group in nucleosides). Nucleosides and nucleotides may also be interchangeably referred to as "units" or "monomers".

[0034] Modified nucleoside

[0035] As used herein, the term "modified nucleoside" or "nucleoside modification" means a nucleoside that has been modified relative to an equivalent DNA or RNA nucleoside by the introduction of one or more modifications to the sugar moiety or the (nucleo)base moiety. In a preferred embodiment, the modified nucleoside contains a modified sugar moiety. The term modified nucleoside may also be used interchangeably herein with terms such as "nucleoside analogue" or modified "unit" or modified "monomer". Nucleosides having an unmodified DNA or RNA sugar moiety are referred to herein as DNA or RNA nucleosides. Nucleosides containing a modification in the base region of a DNA or RNA nucleoside are generally still referred to as DNA or RNA if Watson Crick base pairing is permitted.

[0036] Modified internucleoside bond

[0037] The term "modified internucleoside bond", as defined to those of ordinary skill in the art, refers to a bond other than a phosphodiester (PO) bond that can covalently couple two nucleosides together. Thus, the oligonucleotides of the present invention may contain modified internucleoside bonds. In certain embodiments, the modified internucleoside bonds may increase the nuclease resistance of the oligonucleotides compared to phosphodiester bonds. For naturally occurring oligonucleotides, the internucleoside bond includes a phosphate group that forms a phosphodiester bond between adjacent nucleosides. Modified internucleoside bonds can be particularly useful for stabilizing oligonucleotides for in vivo use and can be used to prevent nuclease cleavage of regions of DNA or RNA nucleosides in the oligonucleotides of the present invention, such as in the gap region G of a nicked oligonucleotide and in regions of modified nucleosides, such as regions F and F'.

[0038] In one embodiment, the oligonucleotide comprises one or more internucleoside linkages modified from natural phosphodiesters, such as one or more modified internucleoside linkages, which are, for example, more resistant to nuclease attack. Nuclease resistance can be determined by incubating the oligonucleotide in serum or by using a nuclease resistance assay (such as snake venom phosphodiesterase (SVPD)), both of which are known in the art. Internucleoside linkages capable of enhancing the nuclease resistance of oligonucleotides are referred to as nuclease-resistant internucleoside linkages. In some embodiments, at least 50% of such internucleoside linkages in the oligonucleotide or its contiguous nucleotide sequence are modified, such as at least 60%, such as at least 70%, such as at least 75%, such as at least 80%, or such as at least 90% of such internucleoside linkages in the oligonucleotide or its contiguous nucleotide sequence are modified. In certain embodiments, the modification extends to all of the internucleoside linkages of the oligonucleotide or its contiguous nucleotide sequence. It should be understood that in certain embodiments, the nucleosides linking the oligonucleotides of the present invention to non-nucleotide functional groups such as conjugates may be phosphodiesters. In certain embodiments, all of the internucleoside linkages of the oligonucleotide or its contiguous nucleotide sequence are nuclease-resistant internucleoside linkages.

[0039] The modified internucleoside linkages can be selected from the group consisting of phosphorothioates, diphosphorothioates, and boranophosphates. In some embodiments, such modified internucleoside linkages are compatible with ribonuclease H recruitment of the oligonucleotides of the present invention, such as phosphorothioates, diphosphorothioates, or boranophosphates.

[0040] In some embodiments, the internucleoside linkage contains sulfur (S), such as a phosphorothioate internucleoside linkage.

[0041] It is advantageous to use phosphorothioate internucleoside linkages in the oligonucleotides of the present invention.

[0042] Phosphorothioate internucleoside linkages are particularly suitable because they have nuclease resistance, good pharmacokinetics, and are easy to manufacture. In certain embodiments, at least 50% of the internucleoside linkages in the oligonucleotide or its contiguous nucleotide sequence are phosphorothioates, such as at least 60%, such as at least 70%, such as at least 75%, such as at least 80%, or such as at least 90% of the internucleoside linkages in the oligonucleotide or its contiguous nucleotide sequence are phosphorothioates. In certain embodiments, all of the internucleoside linkages in the oligonucleotide or its contiguous nucleotide sequence are phosphorothioates.

[0043] In some embodiments, in addition to phosphorothioate linkages, the oligonucleotides of the invention contain phosphorothioate internucleoside linkages and at least one phosphodiester linkage, such as 2, 3 or 4 phosphodiester linkages. In the nicked oligonucleotides, the phosphodiester linkages (when present) are suitably not between consecutive DNA nucleosides in the nick region G.

[0044] In some embodiments, the oligonucleotide contains one or more neutral internucleoside linkages, particularly internucleoside linkages selected from phosphotriesters, methylphosphonates, MMI, amide-3, acetals or thioacetals.

[0045] Further internucleoside linkages are disclosed in WO2009 / 124238 (incorporated herein by reference). In one embodiment, the internucleoside linkage is selected from the linkers disclosed in WO2007 / 031091 (incorporated herein by reference). In particular, the internucleoside linkage can be selected from -O-P(O)2-O-, -O-P(O,S)-O-, -O-P(S)2-O-, -S-P(O)2-O-, -S-P(O,S)-O-, -S-P(S)2-O-, -O-P(O)2-S-, -O-P(O,S)-S-, -S-P(O)2-S-, -O-PO(RH)-O-, O-PO(OCH3)-O-, -O-PO(NRH)-O-, -O-PO(OCH2CH2S-R)-O-, -O-PO(BH3)-O-, -O-PO(NHRH)-O-, -O-P(O)2-NRH-, -NRH-P(O)2-O-, -NRH-CO-O-, -NRH-CO-NRH-, and / or the internucleoside linker can be selected from the group consisting of: -O-CO-O-, -O-CO-NRH-, -NRH-CO-CH2-, -O-CH2-CO-NRH-, -O-CH2-CH2-NRH-, -CO-NRH-CH2-, -CH2-NRHCO-, -O-CH2-CH2-S-, -S-CH2-CH2-O-, -S-CH2-CH2-S-, -CH2-SO2-CH2-, -CH2-CO-NRH-, -O-CH2-CH2-NRH-CO-, -CH2-NCH3-O-CH2-, where RH is selected from hydrogen and C1-4-alkyl.

[0046] Nuclease-resistant linkages, such as phosphorothioate linkages, are particularly useful for oligonucleotide regions that are capable of recruiting nucleases when forming a duplex with a target nucleic acid, such as region G of a nicked body. However, phosphorothioate linkages can also be used in non-nuclease-recruiting regions and / or affinity-enhancing regions, such as regions F and F' of a nicked body. In some embodiments, the nicked body oligonucleotide can include one or more phosphodiester linkages in region F or F', or both regions F and F', where all internucleoside linkages in region G can be phosphorothioates.

[0047] Advantageously, all of the internucleoside linkages of the contiguous nucleotide sequence of the oligonucleotide are phosphorothioates, or all of the internucleoside linkages of the oligonucleotide are phosphorothioate linkages.

[0048] Nucleobase

[0049] The term nucleobase includes the purine (e.g., adenine and guanine) and pyrimidine (e.g., uracil, thymine, and cytosine) moieties present in nucleosides and nucleotides, which form hydrogen bonds in nucleic acid hybridization. Within the scope of the present invention, the term nucleobase also encompasses modified nucleobases that are different from naturally occurring nucleobases but are functional during nucleic acid hybridization. In this specification, "nucleobase" refers to naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine, and hypoxanthine, as well as non-naturally occurring variants. Such variants are described, for example, by Hirao et al. (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.

[0050] In certain embodiments, the nucleobase moiety is modified by altering a purine or pyrimidine to a modified purine or pyrimidine, such as a substituted purine or a substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thiazolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil, 5-thiazolo-uracil, 2-thiouracil, 2'-thiothymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine, and 2-chloro-6-aminopurine.

[0051] The nucleobase moiety can be represented by the letter code of each corresponding nucleobase, e.g., A, T, G, C, or U, where each letter can optionally include modified nucleobases with equivalent functionality. For example, in an exemplary oligonucleotide, the nucleobase moiety is selected from A, T, G, C, and 5-methylcytosine. Optionally, 5-methylcytosine LNA nucleosides can be used in LNA nicked bodies.

[0052] Modified oligonucleotide

[0053] The term "modified oligonucleotide" describes an oligonucleotide that contains one or more sugar-modified nucleosides and / or modified internucleoside linkages. In some literature, the term "chimeric oligonucleotide" is used to describe an oligonucleotide having modified nucleosides.

[0054] Complementarity

[0055] The term "complementarity" is used to describe the Watson-Crick base-pairing ability of nucleosides / nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T) / uracil (U). It should be understood that an oligonucleotide may contain nucleosides having modified nucleobases, for example, 5-methylcytosine is often used to replace cytosine, and thus the term complementarity includes Watson-Crick base pairing between unmodified and modified nucleobases (see, for example, Hirao et al. (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl 37 1.4.1).

[0056] As used herein, "% complementarity" refers to the proportion (percentage) of nucleotides in a continuous nucleotide sequence of a nucleic acid molecule (such as an oligonucleotide) that are complementary to a reference sequence (such as a target sequence or sequence motif), where the nucleic acid molecule spans the continuous nucleotide sequence. The percentage of complementarity is calculated by first determining the number of aligned nucleobases that are complementary (form Watson-Crick base pairs) between the two sequences (when aligned to the target sequence 5'-3' and the oligonucleotide sequence 3'-5'), dividing that number by the total number of nucleotides in the oligonucleotide, and then multiplying by 100. In such alignments, unaligned (non-base-paired) nucleobases / nucleotides are referred to as mismatches. Insertions and deletions are not allowed when calculating the % complementarity of a continuous nucleotide sequence. It should be understood that when determining complementarity, chemical modifications of the nucleobases may be disregarded as long as the ability of the nucleobases to form Watson-Crick base pairs remains (for example, when calculating % identity, 5'-methylcytosine is considered the same as cytosine).

[0057] "Fully complementary" means having 100% complementarity.

[0058] The following are examples of oligonucleotides that are fully complementary to a target nucleic acid.

[0059] The following are examples of oligonucleotides (SEQ ID NO: 49) that are completely complementary to the target nucleic acid (SEQ ID NO: 4).

[0060] 5’gaaggttgaaatgagaattgatttgagttaaa 3’(SEQ ID NO: 4)

[0061] 3’actcttaactaaactcaatt 5’(SEQ ID NO: 49)

[0062] Identity

[0063] As used herein, "identity" means the proportion (percentage) of nucleotides that are exactly the same as a reference sequence (such as a sequence motif) in a continuous nucleotide sequence of a nucleic acid molecule (such as an oligonucleotide), where the nucleic acid molecule spans the continuous nucleotide sequence. The percentage of identity is calculated by determining the number of aligned nucleobases that are the same (a match) between two sequences (in the continuous nucleotide sequence of a compound of the invention and in the reference sequence), dividing that number by the total number of nucleotides in the oligonucleotide, and then multiplying by 100. Thus, the percentage of identity = (number of matches x 100) / length of the aligned region (such as the continuous nucleotide sequence). Insertions and deletions are not made to the sequences when calculating the percentage of identity of a continuous nucleotide sequence. It should be understood that when determining identity, chemical modifications of the nucleobases may be disregarded as long as the function of forming Watson-Crick base pairs is retained (e.g., 5'-methylcytosine is considered the same as cytosine when calculating % identity).

[0064] Hybridization

[0065] As used herein, "hybridization" refers to the formation of hydrogen bonds between base pairs on opposite strands of two nucleic acids (e.g., one oligonucleotide strand and one target nucleic acid strand), thereby forming a duplex. The binding affinity between two nucleic acid strands refers to the strength of hybridization. It is typically described by the melting temperature (Tm), which is defined as the temperature at which half of the oligonucleotide forms a duplex with the target nucleic acid. Under physiological conditions, Tm is not exactly proportional to the affinity (Mergny and Lacroix, 2003, Oligonucleotides 13:515 - 537). The standard state Gibbs free energy ΔG° more accurately represents the binding affinity and has the relationship ΔG° = -RTln(Kd) with the dissociation constant (Kd) of the reaction, where R is the gas constant and T is the absolute temperature. Thus, a very low ΔG° for the reaction between an oligonucleotide and a target nucleic acid reflects strong hybridization between the oligonucleotide and the target nucleic acid. ΔG° is the energy associated with a reaction having a water concentration of 1 M, a pH of 7, and a temperature of 37°C. The hybridization of an oligonucleotide to a target nucleic acid is a spontaneous reaction, and the ΔG° of a spontaneous reaction is less than zero. ΔG° can be measured experimentally, for example, using isothermal titration calorimetry (ITC) as described by Hansen et al. in Chem. Comm. 36 - 38 in 1965 and Holdgate et al. in Drug DiscovToday in 2005. Those of ordinary skill in the art will know that commercial devices for measuring ΔG° are available on the market. ΔG° can also be estimated numerically, for example, by using the nearest neighbor model described by SantaLucia in Proc Natl Acad Sci USA. 95:1460 - 1465 in 1998 or by using appropriate thermodynamic parameters described by Sugimoto et al. in Biochemistry 34:11211 - 11216 in 1995 and McTigue et al. in Biochemistry 43:5388 - 5405 in 2004. In order to be able to modulate the desired nucleic acid target of the oligonucleotides of the present invention via hybridization, an oligonucleotide having a length of 10 - 30 nucleotides is hybridized to the target nucleic acid with an estimated ΔG° value of less than -10 kcal. In certain embodiments, the degree or strength of hybridization is measured by the standard state Gibbs free energy ΔG°. An oligonucleotide having a length of 8 to 30 nucleotides can be hybridized to the target nucleic acid with an estimated ΔG° value in the range of less than -10 kcal, such as less than -15 kcal, such as less than -20 kcal, and such as less than -25 kcal. In certain embodiments, the oligonucleotide is hybridized to the target nucleic acid with an estimated ΔG° value of -10 to -60 kcal, such as -12 to -40 kcal, such as from -15 to -30 kcal or -16 to -27 kcal, such as -18 to -25 kcal.

[0066] target nucleic acid

[0067] According to the present invention, the target nucleic acid is a nucleic acid encoding mammalian Tau and can be, for example, a gene, RNA, mRNA, and pre-mRNA, mature mRNA, or cDNA sequence. Thus, the target can thus be referred to as a Tau target nucleic acid or a MAPT target nucleic acid, and these terms can be used interchangeably. The oligonucleotides of the present invention can, for example, target exon regions of mammalian MAPT, or can, for example, target intron regions in MAPT pre-mRNA (see Table 1).

[0068] Table 1. Exons and Introns of Human MAPT

[0069]

[0070]

[0071] Suitably, the target nucleic acid encodes a Tau protein, particularly mammalian Tau, such as human Tau (see, for example, Tables 2 and 3, which provide pre-mRNA sequences for human and monkey Tau).

[0072] In certain embodiments, the target nucleic acid is selected from the group consisting of SEQ ID NOs: 1 and 2 or naturally occurring variants thereof (such as sequences encoding mammalian Tau proteins). If the oligonucleotides of the present invention are used in research or diagnosis, the target nucleic acid can be cDNA or synthetic nucleic acid derived from DNA or RNA.

[0073] For in vivo or in vitro applications, the oligonucleotides of the present invention are generally capable of inhibiting Tau protein expression in cells expressing the MAPT target nucleic acid. The consecutive sequence of the nucleobases of the oligonucleotides of the present invention, as measured over the entire length of the oligonucleotide, is generally complementary to the MAPT target nucleic acid, optionally with the exception of one or two mismatches, and optionally does not contain a nucleotide-based linker region capable of linking the oligonucleotide to an optional functional group such as a conjugate or other non-complementary terminal nucleotides (such as region D' or D"). In certain embodiments, the target nucleic acid can be RNA or DNA, such as messenger RNA, such as mature mRNA or pre-mRNA.

[0074] In certain embodiments, the target nucleic acid is RNA or DNA encoding a mammalian Tau protein, such as human Tau, such as the human MAPT pre-mRNA sequence, such as that disclosed in SEQ ID NO: 1. Further information on exemplary target nucleic acids is provided in Tables 2 and 3.

[0075] Table 2. Tau Cross-Species Genomic and Assembly Information.

[0076]

[0077] Fwd = Forward strand. Genomic coordinates provide the pre-mRNA sequence (genomic sequence). NCBI reference provides the mRNA sequence (cDNA sequence).

[0078] * The National Center for Biotechnology Information (NCBI) Reference Sequence Database is a comprehensive, integrated, non-redundant, and well-annotated collection of reference sequences, including genomic, transcript, and protein. Its website is www.ncbi.nlm.nih.gov / refseq.

[0079] Table 3. Tau / MAPT Cross-Species Sequence Details.

[0080]

[0081] Target Sequence

[0082] As used herein, "target sequence" refers to a sequence of nucleotides present in a target nucleic acid that contains a nucleobase sequence complementary to the oligonucleotide of the present invention. In certain embodiments, the target sequence comprises a region on the target nucleic acid, the nucleobase sequence of which is complementary to the contiguous nucleotide sequence of the oligonucleotide of the present invention. This region of the target nucleic acid may also be interchangeably referred to as the target nucleotide sequence, target sequence, or target region. In certain embodiments, the target sequence is longer than the complementary sequence of a single oligonucleotide and may, for example, represent a region of the target nucleic acid that is more readily targeted by several oligonucleotides of the present invention.

[0083] In some embodiments, the target sequence is selected from the sequences of any region in Table 4 (R_1 to R_2254). In particular, the target sequence may be selected from one of the regions within the group consisting of R_223, R_738, or R_1298.

[0084] Table 4. Regions (reg.) on SEQ ID NO: 1 that can be targeted using the oligonucleotides of the present invention

[0085]

[0086]

[0087]

[0088]

[0089]

[0090]

[0091]

[0092]

[0093]

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[0100]

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113] In some embodiments, the target sequence is selected from human MAPT mRNA introns, such as the sequences of Tau human mRNA introns 1 or 2 (see Table 1 above).

[0114] The oligonucleotides of the present invention comprise a continuous nucleotide sequence that is complementary or hybridizes to the target nucleic acid, such as the target sequences described herein.

[0115] The target sequence that is complementary or hybridizes to the oligonucleotide typically comprises a continuous nucleobase sequence having at least 10 nucleotides. The continuous nucleotide sequence ranges from 10 to 100 nucleotides, such as 12 to 60, such as 13 to 50, such as 14 to 30, such as 15 to 25, such as 16 to 20 consecutive nucleotides.

[0116] In one embodiment of the present invention, the target sequence is SEQ ID NO: 3, corresponding to region A. In certain embodiments, the target sequence is selected from positions 12051 to 12111 of SEQ ID NO: 1, such as positions 12051 to 12079, positions 12085 to 12111, or positions 12060 to 12078 of SEQ ID NO: 1.

[0117] In another embodiment of the present invention, the target sequence is SEQ ID NO: 4, corresponding to region B. In certain embodiments, the target sequence is selected from positions 39562 to 39593 of SEQ ID NO: 1, such as positions 39573 to 39592 of SEQ ID NO: 1.

[0118] In another embodiment of the present invention, the target sequence is SEQ ID NO: 5, corresponding to region C. In certain embodiments, the target sequence is selected from positions 72837 to 72940 of SEQ ID NO: 1, such as positions 72861 to 72891 or positions 72862 to 72890 of SEQ ID NO: 1.

[0119] Target cell

[0120] As used herein, the term "target cell" refers to a cell that is expressing a target nucleic acid. In certain embodiments, the target cell can be in vivo or in vitro. In certain embodiments, the target cell is a mammalian cell, such as a rodent cell, such as a mouse cell or a rat cell, or a primate cell, such as a monkey cell or a human cell.

[0121] In a preferred embodiment, the target cell expresses Tau mRNA, such as Tau pre-mRNA or Tau mature mRNA. The poly-A tail of Tau mRNA is generally ignored in antisense oligonucleotide targeting.

[0122] Naturally occurring variant

[0123] The term "naturally occurring variant" refers to a variant of the MAPT gene or transcript that is derived from the same locus as the target nucleic acid and may differ, for example, due to genetic code degeneracy where multiple codons encode the same amino acid, or due to alternative splicing of pre-mRNA, or the presence of polymorphisms such as single nucleotide polymorphisms (SNPs) and allelic variants. Under conditions of sufficient complementary sequence with the oligonucleotide, the oligonucleotides of the invention can thus target the target nucleic acid and its naturally occurring variants.

[0124] In some embodiments, the naturally occurring variant has at least 95%, such as at least 98% or at least 99% homology with the mammalian MAPT target nucleic acid, such as a target nucleic acid selected from the group consisting of SEQ ID NO: 1 and 2. In certain embodiments, the naturally occurring variant has at least 99% homology with the human MAPT target nucleic acid of SEQ ID NO: 1.

[0125] Regulation of expression

[0126] As used herein, the term "modulation of expression" is a general term used to describe the ability of the oligonucleotide to alter the amount of Tau compared to the amount of Tau prior to administration of the oligonucleotide. Alternatively, modulation of expression can be determined with reference to a control experiment. As is well known, a control group is an individual or target cell treated with a saline composition or an individual or target cell treated with a non-targeting oligonucleotide (mock).

[0127] One type of modulation is the ability of the oligonucleotide to inhibit, downregulate, reduce, suppress, eliminate, stop, block, prevent, alleviate, lower, avoid or terminate Tau expression, for example, by degrading mRNA or blocking transcription. Another type of modulation is the ability of the oligonucleotide to restore, increase or enhance Tau expression, for example, by repairing splice sites or preventing splicing or removing or blocking inhibitory mechanisms such as microRNA repression.

[0128] High-affinity modified nucleoside

[0129] A high-affinity modified nucleoside is a modified nucleoside that, when incorporated into the oligonucleotide, can enhance the affinity of the oligonucleotide for its complementary target, for example, as measured by the melting temperature (T m)The measured ones. The high-affinity modified nucleosides of the present invention preferably cause an increase in the melting temperature of each modified nucleoside of +0.5 to +12 °C, more preferably +1.5 to +10 °C, and most preferably +3 to +8 °C. There are numerous well-known high-affinity modified nucleosides in this technical field, including, for example, many 2'-substituted nucleosides and locked nucleic acids (LNAs) (see, for example, Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213).

[0130] Sugar modification

[0131] The oligomers of the present invention may comprise one or more nucleosides having modified sugar moieties, i.e., sugar moieties that are modified compared to the ribose moiety in DNA and RNA.

[0132] Numerous nucleosides containing modified ribose moieties have been made, mainly for the purpose of improving specific properties of oligonucleotides, such as affinity and / or nuclease resistance.

[0133] These modifications include modifications to the ribose ring structure, such as substitution with a hexose ring (HNA), or bicyclic (LNA) usually having a biradical bridge between the C2 and C4 carbon atoms on the ribose ring, or unlinked ribose rings (such as UNA) usually having no bond between the C2 and C3 carbon atoms. Other sugar-modified nucleosides include, for example, bicyclohexose nucleic acids (WO2011 / 017521) or tricyclic nucleic acids (WO2013 / 154798). Modified nucleosides also include nucleosides in which the sugar moiety is replaced with a non-sugar moiety, such as in the case of peptide nucleic acids (PNAs) or morpholino nucleic acids.

[0134] Sugar modification also includes modification by changing the substituent groups on the ribose ring to groups other than the hydrogen or 2'-OH groups that naturally exist in DNA and RNA nucleosides. Substituents can be introduced, for example, at the 2', 3', 4', or 5' positions.

[0135] 2'-sugar modified nucleosides

[0136] 2'-sugar modified nucleosides are nucleosides having a substituent other than H or -OH at the 2' position (2'-substituted nucleosides) or nucleosides containing a 2'-linked biradical capable of forming a bridge between the 2' carbon and a second carbon in the ribose ring, such as LNA (2'-4' biradical bridge) nucleosides.

[0137] More precisely, the development of 2'-sugar substituted nucleosides has received much attention, and many 2'-substituted nucleosides have been found to have helpful properties when incorporated into oligonucleotides. For example, 2'-modified sugars can enhance the binding affinity of the oligonucleotide and / or increase the nuclease resistance of the oligonucleotide. Examples of 2'-substituted modified nucleosides include 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA, and 2'-F-ANA nucleosides. For more examples, see, for example, Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213, as well as Deleavey and Damha, Chemistry and Biology 2012, 19, 937. The following are diagrams of 2'-substituted modified nucleosides.

[0138]

[0139] In the present invention, 2'-substituted sugar modified nucleosides do not include 2'-bridged nucleosides such as LNA.

[0140] Locked nucleic acid nucleoside (LNA nucleoside)

[0141] An "LNA nucleoside" is a 2'-sugar modified nucleoside that contains a biradical (also referred to as a "2'-4' bridge") that links the C2' and C4' of the ribose ring of the nucleoside, which can restrict or lock the conformation of the ribose ring. These nucleosides are also referred to in the literature as bridged nucleic acids or bicyclic nucleic acids (BNA). Locking the conformation of the ribose can enhance the hybridization affinity (duplex stabilization) when LNA is incorporated into an oligonucleotide to generate a complementary RNA or DNA molecule. This can be routinely determined by measuring the melting temperature of the oligonucleotide / complement duplex.

[0142] Non-limiting examples of LNA nucleosides are disclosed in WO 99 / 014226, WO 00 / 66604, WO 98 / 039352, WO2004 / 046160, WO 00 / 047599, WO 2007 / 134181, WO 2010 / 077578, WO 2010 / 036698, WO2007 / 090071, WO 2009 / 006478, WO2011 / 156202, WO 2008 / 154401, WO 2009 / 067647, WO2008 / 150729, Morita et al., Bioorganic & Med. Chem. Lett. 12, 73 - 76, Seth et al. J. Org. 2010, Vol 75(5) pp. 1569 - 81, Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225 - 1238, and Wan and Seth, J. Medical Chemistry 2016, 59, 9645 - 9667.

[0143] The 2′-4’ bridge contains 2 to 4 bridging atoms, in particular of the formula -X-Y-, where

[0144] X is oxygen, sulfur, -CR a R b -, -C(R a )=C(R b )-, -C(=CR a R b )-, -C(R a )=N-, -Si(R a ) 2 -, -SO 2 -, -NR a -; -O-NR a -, -NR a -O-, -C(=J)-, Se, -O-NR a -, -NR a -CR a R b -, -N(R a )-O- or -O-CR a R b -;

[0145] Y is oxygen, sulfur, -(CR a R b ) n -, -CR a R b -O-CR a R b-, -C(R a )=C(R b )-, -C(R a )=N-, -Si(R a ) 2 -, -SO 2 -, -NR a -, -C(=J)-, Se, -O-NR a -, -NR a -CR a R b -, -N(R a )-O- or -O-CR a R b -;

[0146] However, -X-Y- is not O-O-, Si(R a ) 2 -Si(R a ) 2 -, -SO 2 -SO 2 -, -C(R a )=C(R b )-C(R a )=C(R b )-, -C(R a )=N-C(R a )=N-, -C(R a )=N-C(R a )=C(R b )-, -C(R a )=C(R b )-C(R a )=N- or -Se-Se-;

[0147] J is oxygen, sulfur, =CH 2 or ==N(R a );

[0148] R a and R bare independently selected from hydrogen, halogen, hydroxy, cyano, thiohydroxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl, aryl, heterocyclyl, amino, alkylamino, carbamoyl, alkylaminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, alkylcarbonylamino, urea, alkanoyloxy, sulfonyl, alkylsulfonyloxy, nitro, azido, thiohydroxythioetheralkylsulfhydryl, aryloxycarbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxycarbonyl, heteroaryloxy, heteroarylcarbonyl, -OC(=X a )R c 、-OC(=X a )NR c R d and-NR e C(=X a )NR c R d ;

[0149] or two pairs of R a and R b together to form an optionally substituted methylene group;

[0150] or two pairs of R a and R b Together with the carbon atoms to which they are attached, they form a cycloalkyl or halocycloalkyl, with only one carbon atom halocycloalkyl (only one carbon atom of -XY-);

[0151] wherein substituted alkyl, substituted alkenyl, substituted alkynyl, substituted alkoxy and substituted methylene are alkyl, alkenyl, alkynyl, alkoxy and methylene substituted with 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl, heterocyclyl, aryl and heteroaryl;

[0152] X a Oxygen, sulfur or -NR c ;

[0153] R c , R d and R e are independently selected from hydrogen and alkyl; and

[0154] n is 1, 2 or 3.

[0155] In another embodiment of the present invention, X is oxygen, sulfur, -NR a -、-CR a R b-or -C(=CR a R b )-, especially oxygen, sulfur, -NH-, -CH 2 -or -C(=CH 2 )-, more especially oxygen.

[0156] In another specific embodiment of the present invention, Y is -CR a R b -, -CR a R b -CR a R b -or -CR a R b -CR a R b- CR a R b -, especially -CH 2 -CHCH 3 -,-CHCH 3 -CH 2 -,-CH 2 -CH 2 -or -CH 2 -CH 2 -CH 2 -.

[0157] In a specific embodiment of the present invention, -X-Y- is -O-(CR a R b ) n -,-S-CR a R b -,-N(R a )CR a R b -,-CR a R b -CR a R b -,-O-CR a R b -O-CR a R b -,-CR a R b -O-CR a R b -,-C(=CR a R b )-CR a R b -,-N(R a )CR a R b -,-O-N(R a )-CR aR b - or -N(R a )-O-CR a R b -.

[0158] In one specific embodiment of the present invention, R a and R b are independently selected from the group consisting of hydrogen, halogen, hydroxyl, alkyl, and alkoxyalkyl, especially hydrogen, halogen, alkyl, and alkoxyalkyl.

[0159] In another embodiment of the present invention, R a and R b are independently selected from the group consisting of hydrogen, fluoro group, hydroxyl, methyl, and -CH 2 -O-CH 3 , especially hydrogen, fluoro group, methyl, and -CH 2 -O-CH 3 .

[0160] Advantageously, one of R a and R b in -X-Y- is defined as above, and the others are all hydrogen at the same time.

[0161] In another specific embodiment of the present invention, R a is hydrogen or alkyl, especially hydrogen or methyl.

[0162] In another specific embodiment of the present invention, R b is hydrogen or alkyl, especially hydrogen or methyl.

[0163] In one specific embodiment of the present invention, one or both of R a and R b are hydrogen.

[0164] In one specific embodiment of the present invention, only one of R a and R b is hydrogen.

[0165] In one specific embodiment of the present invention, one of R a and R b is methyl and the other is hydrogen.

[0166] In one specific embodiment of the present invention, both R a and R b are methyl at the same time.

[0167] In one specific embodiment of the present invention, -X-Y- is -O-CH 2 -, -S-CH 2 -, -S-CH(CH 3)-, -NH-CH 2 )-, -O-CH 2 CH 2 )-, -O-CH(CH 2 -O-CH 3 )-, -O-CH(CH 2 CH 3 )-, -O-CH(CH 3 )-, -O-CH 2 -O-CH 2 )-, -O-CH 2 -O-CH 2 )-, -CH 2 -O-CH 2 )-, -C(=CH 2 )CH 2 )-, -C(=CH 2 )CH(CH 3 )-, -N(OCH 3 )CH 2 - or -N(CH 3 )CH 2 -;

[0168] In one specific embodiment of the present invention, -X-Y- is -O-CR a R b -, where R a and R b are independently selected from the group consisting of hydrogen, alkyl, and alkoxyalkyl, particularly hydrogen, methyl, and -CH 2 -O-CH 3 .

[0169] In one specific embodiment, -X-Y- is -O-CH 2 - or -O-CH(CH 3 )-, particularly -O-CH 2 -.

[0170] The 2'-4' bridge can be located below the plane of the ribose ring (β-D-configuration) or above the plane of the ring (α-L-configuration), as shown respectively in Formula (A) and Formula (B).

[0171] The LNA nucleosides according to the present invention are particularly those of Formula (A) or (B)

[0172]

[0173] where

[0174] W is oxygen, sulfur, -N(R a )-, or -CR a R b -, particularly oxygen;

[0175] B is a nucleobase or a modified nucleobase;

[0176] Z is an internucleoside bond to an adjacent nucleoside or a 5′-terminal group;

[0177] Z* is an internucleoside bond to an adjacent nucleoside or to the 3′-terminal group;

[0178] R 1 , R 2 , R 3 , R 5 and R 5* are independently selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkyl, azido, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl, and aryl; and

[0179] X, Y, R a and R b As defined above.

[0180] In one embodiment, in the definition of -XY-, R a In another embodiment, in the definition of -XY-, R b In a further embodiment, in the definition of -XY-, R a and R b In one embodiment, in the definition of -XY-, R a and R b In one embodiment, in the definition of -XY-, R a and R b In one embodiment, in the definition of -XY-, R a and R b Both are methyl groups.

[0181] In a further embodiment, in the definition of X, R a In another embodiment, in the definition of X, R b is hydrogen or alkyl, in particular hydrogen or methyl. In one embodiment, in the definition of X, R a and R b In one embodiment, in the definition of X, R a and R b In one embodiment, in the definition of X, R a and R bOne of them is methyl and the other is hydrogen. In a specific embodiment, in the definition of X, R a and R b are both methyl at the same time.

[0182] In a further specific embodiment, in the definition of Y, R a is hydrogen or alkyl, especially hydrogen or methyl. In another specific embodiment, in the definition of Y, R b is hydrogen or alkyl, especially hydrogen or methyl. In a specific embodiment, in the definition of Y, R a and R b one or both of them are hydrogen. In a specific embodiment, in the definition of Y, R a and R b only one of them is hydrogen. In a specific embodiment, in the definition of Y, R a and R b one of them is methyl and the other is hydrogen. In a specific embodiment, in the definition of Y, R a and R b are both methyl at the same time.

[0183] In a specific embodiment of the present invention, R 1 、R 2 、R 3 、R 5 and R 5* are independently selected from hydrogen and alkyl, especially hydrogen and methyl.

[0184] In another specific embodiment of the present invention, R 1 、R 2 、R 3 、R 5 and R 5* are all hydrogen at the same time.

[0185] In another specific embodiment of the present invention, R 1 、R 2 、R 3 are all hydrogen at the same time, and one of R 5 and R 5* is hydrogen and the other is as defined above, especially alkyl, more especially methyl.

[0186] In a specific embodiment of the present invention, R 5 and R 5* are independently selected from hydrogen, halogen, alkyl, alkoxyalkyl and azide, especially selected from hydrogen, fluorine, methyl, methoxyethyl and azide. In a particularly advantageous embodiment of the present invention, R 5 and R 5*One of them is hydrogen and the other is an alkyl group, in particular a methyl group, a halogen, in particular fluorine, an alkoxyalkyl group, in particular a methoxyethyl group, or an azide group; or R 5 and R 5* both are hydrogen or a halogen at the same time, in particular both are hydrogen or fluorine at the same time. In these specific embodiments, W can advantageously be oxygen, and -X-Y- is advantageously -O-CH 2 -.

[0187] In a specific embodiment of the present invention, -X-Y- is -O-CH 2 -, W is oxygen and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time. These LNA nucleosides are disclosed in WO 99 / 014226, WO 00 / 66604, WO 98 / 039352 and WO 2004 / 046160, which are all incorporated herein by reference, and include the commonly known β-D-oxy-LNA and α-L-oxy-LNA nucleosides in the art.

[0188] In another specific embodiment of the present invention, -X-Y- is -S-CH 2 ]-, W is oxygen, and R 1 , R 2 , R 3 , R 5 , R 5* are all hydrogen at the same time. These thio-LNA nucleosides are disclosed in WO 99 / 014226 and WO 2004 / 046160, which are incorporated herein by reference.

[0189] In another specific embodiment of the present invention, -X-Y- is -NH-CH 2 -, W is oxygen, and R 1 , R 2 , R 3 , R 5 , R 5* are all hydrogen at the same time. These amino-LNA nucleosides are disclosed in WO 99 / 014226 and WO 2004 / 046160, which are incorporated herein by reference.

[0190] In another specific embodiment of the present invention, -X-Y- is -O-CH 2 CH 2 - or -OCH 2 CH 2 CH 2 , W is oxygen, and R 1 , R 2 , R 3, R 5 and R 5* are both hydrogen at the same time. These LNA nucleosides are disclosed in WO 00 / 047599 and Morita et al., Bioorganic & Med. Chem. Lett. 12, 73 - 76, which are hereby incorporated by reference, and include those commonly known in the art such as 2′-O-4'C-ethylene bridged nucleic acid (ENA).

[0191] In another embodiment of the present invention, -X-Y- is -O-CH 2 -, W is oxygen, R 1 , R 2 , R 3 are all hydrogen at the same time, one of R 5 and R 5* is hydrogen, and the other is not hydrogen, such as an alkyl group, for example, methyl. These 5'-substituted nucleosides are disclosed in WO2007 / 134181, which is hereby incorporated by reference.

[0192] In another embodiment of the present invention, -X-Y- is -O-CR a R b , where one or both of R a and R b are not hydrogen, especially an alkyl group, such as methyl, W is oxygen, R 1 , R 2 , R 3 are all hydrogen at the same time, one of R 5 and R 5* is hydrogen, and the other is not hydrogen, especially an alkyl group, for example, methyl. These bis modified LNA nucleosides are disclosed in WO 2010 / 077578, which is hereby incorporated by reference.

[0193] In another embodiment of the present invention, -X-Y- is -O-CHR a -, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time. These 6'-substituted LNA nucleosides are disclosed in WO 2010 / 036698 and WO 2007 / 090071, both of which are hereby incorporated by reference. Among these 6′-substituted LNA nucleosides, R a is especially C 1- C 6An alkyl group, such as a methyl group.

[0194] In another specific embodiment of the present invention, -X-Y- is -O-CH(CH 2 -O-CH 3 )- (「2’O-methoxyethylbicyclic nucleic acid」, Seth et al., J. Org. Chem. 2010, Vol 75(5) pp. 1569 - 81).

[0195] In another specific embodiment of the present invention, -X-Y- is -O-CH(CH 2 CH 3 )- (「2’O-methoxyethylbicyclic nucleic acid」, Seth et al., J. Org. Chem. 2010, Vol 75(5) pp. 1569 - 81).

[0196] In another specific embodiment of the present invention, -X-Y- is -O-CH(CH 2 -O-CH 3 )-, W is oxygen, and R 1 、R 2 、R 3 、R 5 and R 5* are all simultaneously hydrogen. These LNA nucleosides are also known as cyclic MOE (cMOE) in the art and are disclosed in WO 2007 / 090071.

[0197] In another specific embodiment of the present invention, -X-Y- is -O-CH(CH 3 )-.

[0198] In another specific embodiment of the present invention, -X-Y- is -O-CH 2 -O-CH 2 - (Seth et al. of the same above, J. Org. Chem 2010).

[0199] In another specific embodiment of the present invention, -X-Y- is -O-CH(CH 3 )-, W is oxygen, and R 1 、R 2 、R 3 、R 5 and R 5*are all hydrogen at the same time. These 6'-methyl LNA nucleosides are also known as cET nucleosides in the art and can be the (S)-cET or (R)-cET enantiomers, such as WO 2007 / 090071 (β-D) and WO 2010 / 036698 (α-L), both of which are incorporated herein by reference.

[0200] In another specific embodiment of the present invention, -X-Y- is -O-CR a R b -, where R a and R b are not hydrogen, W is oxygen, and R 1 、R 2 、R 3 、R 5 and R 5* are all hydrogen at the same time. In a specific embodiment, R a and R b are both alkyl groups, especially both are methyl groups at the same time. These 6'-di-substituted LNA nucleosides are disclosed in WO 2009 / 006478, which is incorporated herein by reference.

[0201] In another specific embodiment of the present invention, -X-Y- is -S-CHR a -, W is oxygen, and R 1 、R 2 、R 3 、R 5 and R 5* are all hydrogen at the same time. These 6'-substituted thio-LNA nucleosides are disclosed in WO 2011 / 156202, which is incorporated herein by reference. In a specific embodiment of this 6'-substituted thio-LNA, R a is an alkyl group, especially methyl.

[0202] In a specific embodiment of the present invention, -X-Y- is -C(=CH 2 )C(R a R b )-, -C(=CHF)C(R a R b )- or -C(=CF 2 )C(R a R b )-, W is oxygen and R 1 、R 2 、R 3 、R 5 and R 5* are all hydrogen at the same time. R a and R bThe favorable group is independently selected from hydrogen, halogen, alkyl, and alkoxyalkyl, especially hydrogen, methyl, fluoro group, and methoxymethyl. R a and R b are especially both hydrogen or methyl, or one of R a and R b is hydrogen and the other is methyl. These vinyl carbo LNAnucleosides are disclosed in WO 2008 / 154401 and WO 2009 / 067647, both of which are incorporated herein by reference.

[0203] In one embodiment of the present invention, -X-Y- is -N(OR a )-CH 2 -, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen. In one embodiment, R a is alkyl, such as methyl. These LNA nucleosides are also called N-substituted LNA and are disclosed in WO 2008 / 150729, which is incorporated herein by reference.

[0204] In one embodiment of the present invention, -X-Y- is -O-N(R a )-, -N(R a )-O-, -NR a -CR a R b -CR a R b - or -NR a -CR a R b -, W is oxygen, and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time. R a and R b are favorably independently selected from hydrogen, halogen, alkyl, and alkoxyalkyl, especially hydrogen, methyl, fluoro group, and methoxymethyl. In one embodiment, R a is alkyl, such as methyl, and R b is hydrogen or methyl, especially hydrogen. (Seth et al. of the same above, J. Org Chem 2010).

[0205] In one embodiment of the present invention, -X-Y- is -O-N(CH 3)-(Ibid. Seth et al., J. Org. Chem 2010).

[0206] In a specific embodiment of the present invention, R 5 and R 5* are both hydrogen at the same time. In another specific embodiment of the present invention, one of R 5 and R 5* is hydrogen, and the other is an alkyl group, such as methyl. In these embodiments, R 1 , R 2 and R 3 can particularly be hydrogen and -X-Y- can particularly be -O-CH 2 - or -O-CHC(R a ) 3 -, such as -O-CH(CH 3 )-.

[0207] In a specific embodiment of the present invention, -X-Y- is -CR a R b -O-CR a R b -, such as -CH 2 -O-CH 2 -, W is oxygen and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time. In these specific embodiments, R a can be an alkyl group, such as methyl, R b is hydrogen or methyl, particularly hydrogen. These LNA nucleosides are also called conformationally restricted nucleotides (CRN), and are disclosed in WO 2013 / 036868, which is incorporated herein by reference.

[0208] In a specific embodiment of the present invention, -X-Y- is -O-CR a R b -O-CR a R b -, such as -O-CH 2 -O-CH 2 -, W is oxygen and R 1 , R 2 , R 3 , R 5 and R ” are all hydrogen at the same time. R a and R bThe beneficial group is independently selected from hydrogen, halogen, alkyl and alkoxyalkyl, especially hydrogen, methyl, fluoro group and methoxymethyl. In this specific embodiment, R a can be alkyl, such as methyl, and R b is hydrogen or methyl, especially hydrogen. These LNA nucleosides are also called COC nucleotides and are disclosed in Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225-1238, which is incorporated herein by reference.

[0209] Unless otherwise specified, it will be understood that the LNA nucleoside can be a β-D or α-L stereoisomer.

[0210] Specific examples of the LNA nucleosides of the present invention are presented in Scheme 1 (where B is as defined above).

[0211] Scheme 1

[0212]

[0213] Particular LNA nucleosides are β-D-oxy-LNA, 6'-methyl-β-D-oxy LNA, such as (S)-6'-methyl-β-D-oxy-LNA (ScET) and ENA.

[0214] If one of the starting materials or compounds of the present invention contains one or more functional groups that are unstable or reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups (as described in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 3rd Ed., 1999, Wiley, New York) can be introduced before the key steps using methods well known in the art. These protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature. Examples of protecting groups are tert-butylcarbonyl (Boc), 9-fluorenylmethyl carbamate (Fmoc), 2-trimethylsilylethyl carbamate (Teoc), carbobenzyloxy (Cbz) and p-methoxybenzyloxycarbonyl (Moz).

[0215] The compounds described herein can contain several asymmetric centers and can be in the form of pure enantiomers, mixtures of enantiomers such as racemates, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates.

[0216] The term "asymmetric carbon atom" means a carbon atom having four different substituents. According to the Cahn-Ingold-Prelog sequence rules, an asymmetric carbon atom can be in the "R" or "S" configuration.

[0217] Chemical group definitions

[0218] In this specification, the term "alkyl", alone or in combination, denotes a straight-chain or branched-chain alkyl group having 1 to 8 carbon atoms, particularly a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, and more particularly a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms. Straight-chain and branched-chain C 1 -C 8 Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, isopentyl, isohexyl, isoheptyl, and isooctyl, particularly methyl, ethyl, propyl, butyl, and pentyl. Specific examples of alkyl groups are methyl, ethyl, and propyl.

[0219] The term "cycloalkyl", alone or in combination, denotes a cycloalkyl ring having 3 to 8 carbon atoms, particularly a cycloalkyl ring having 3 to 6 carbon atoms. Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, more specifically cyclopropyl and cyclobutyl. A specific example of "cycloalkyl" is cyclopropyl.

[0220] The term "alkoxy", alone or in combination, denotes a group of the formula alkyl-O-, where the term "alkyl" has the meaning given previously, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, and tert-butoxy. Particular "alkoxy" groups are methoxy and ethoxy. Methoxyethoxy is a specific example of an "alkoxyalkoxy".

[0221] The term "oxy", alone or in combination, denotes the -O- group.

[0222] The term "alkenyl", alone or in combination, denotes a straight-chain or branched-chain hydrocarbon residue containing a carbon-carbon double bond and having up to 8, preferably up to 6, and particularly preferably up to 4 carbon atoms. Examples of alkenyl groups are vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, and isobutenyl.

[0223] The term "alkynyl", alone or in combination, denotes a straight-chain or branched-chain hydrocarbon residue containing a carbon-carbon triple bond and having up to 8, preferably up to 6, and particularly preferably up to 4 carbon atoms.

[0224] The term "halogen" or "halo group", alone or in combination, means fluorine, chlorine, bromine or iodine, and especially fluorine, chlorine or bromine, more especially fluorine. The term "halo group" in combination with another group means that the group is substituted with at least one halogen, especially substituted with one to five halogens, especially one to four halogens, i.e., one, two, three or four halogens.

[0225] The term "haloalkyl", alone or in combination, means an alkyl group substituted with at least one halogen, especially substituted with one to five halogens, especially one to three halogens. Examples of haloalkyl include mono-fluoro-, di-fluoro- or tri-fluoro-methyl, -ethyl or -propyl, such as 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl or trifluoromethyl. Fluoromethyl, difluoromethyl and trifluoromethyl are specific "haloalkyls".

[0226] The term "halocycloalkyl", alone or in combination, means a cycloalkyl group as defined above substituted with at least one halogen, especially substituted with one to five halogens, especially one to three halogens. Specific examples of "halocycloalkyl" are halocyclopropyl, especially fluorocyclopropyl, difluorocyclopropyl and trifluorocyclopropyl.

[0227] The term "hydroxyl (hydroxyl and hydroxy)", alone or in combination, means the -OH group.

[0228] The term "thiohydroxyl or mercapto (thiohydroxyl and thiohydroxy)", alone or in combination, means the -SH group.

[0229] The term "carbonyl", alone or in combination, means the -C(O)- group.

[0230] The term "carboxy (carboxy or carboxyl)", alone or in combination, means the -COOH group.

[0231] The term "amino", alone or in combination, means a primary amino group (-NH 2 ), a secondary amino group (-NH-), or a tertiary amino group (-N-).

[0232] The term "alkylamino", alone or in combination, means an amino group as defined above substituted with one or two alkyl groups as defined above.

[0233] The term "sulfonyl", alone or in combination, means the -SO 2 group.

[0234] The term "sulfinyl", alone or in combination, means the -SO- group.

[0235] The term "sulfanyl", alone or in combination, represents an -S- group.

[0236] The term "cyano", alone or in combination, represents a -CN- group.

[0237] The term "azido", alone or in combination, represents -N 3 group.

[0238] The term "nitro", alone or in combination, represents NO 2 group.

[0239] The term "formyl", alone or in combination, represents a -C(O)H group.

[0240] The term "carbamoyl", alone or in combination, represents -C(O)NH 2 group.

[0241] The term "ureido", alone or in combination, represents -NH-C(O)-NH 2 group.

[0242] The term "aryl", alone or in combination, represents a monocyclic or bicyclic system of a monovalent aromatic carbocyclic ring containing 6 to 10 carbon ring atoms, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenoxy, carboxy, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of aryl include phenyl and naphthyl, especially phenyl.

[0243] The term "heteroaryl", alone or in combination, represents a monocyclic or bicyclic system of a monovalent aromatic heterocyclic ring having 5 to 12 ring atoms, containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenoxy, carboxy, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of heteroaryl include pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzofuryl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuryl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, carbazolyl or acridinyl.

[0244] The term "heterocyclic group", alone or in combination, refers to a monocyclic or bicyclic ring system having 4 to 12, especially 4 to 9 ring atoms, which is a monovalent saturated or partially unsaturated ring system containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, and the remaining ring atoms are carbon, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenoxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of saturated heterocyclic groups are tetrahydroazepinyl, pyrrolidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, tetrahydrothiazolyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxaazepanyl. Examples of bicyclic saturated heterocycloalkyl groups are 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza-bicyclo[3.3.1]nonyl, or 3-thia-9-aza-bicyclo[3.3.1]nonyl. Examples of partially unsaturated heterocycloalkyl groups are dihydrofuryl, imidazolinyl, dihydrooxazolyl, tetrahydropyridyl or dihydropyranyl.

[0245] Pharmaceutically acceptable salts

[0246] The term "pharmaceutically acceptable salts" means salts which retain the biological effectiveness and properties of the free bases or free acids and which are not biologically or otherwise disadvantageous. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, especially hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine. In addition, these salts can be prepared by adding an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary amines, secondary amines, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins. The compounds of formula (I) can also exist in zwitterionic form. Particularly preferred pharmaceutically acceptable salts of the compounds of formula (I) are salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and methanesulfonic acid.

[0247] Protecting group

[0248] The term "protecting group", when used alone or in combination, represents a group that can selectively block reactive positions in a multifunctional compound, allowing a chemical reaction to proceed selectively at another unprotected reactive position. The protecting group can be removed. Exemplary protecting groups are amino protecting groups, carboxyl protecting groups, or hydroxyl protecting groups.

[0249] Nuclease-mediated degradation

[0250] Nuclease-mediated degradation means that an oligonucleotide can mediate the degradation of a sequence when it forms a duplex with a complementary nucleotide sequence.

[0251] In certain embodiments, the oligonucleotide can act via nuclease-mediated degradation of the target nucleic acid, in which the oligonucleotide of the present invention can recruit nucleases, particularly endonucleases, preferably ribonucleases (RNases), such as ribonuclease H. In an example of the design of an oligonucleotide that operates via a nuclease-mediated mechanism, the oligonucleotide typically contains a region of at least 5 or 6 consecutive DNA nucleosides, and affinity-enhancing nucleosides, such as gapmers, headmers, and tailmers, are attached on one or both sides of the region.

[0252] Ribonuclease H activity and recruitment

[0253] The ribonuclease H activity of an antisense oligonucleotide refers to its ability to recruit ribonuclease H when it is in a duplex with a complementary RNA molecule. WO01 / 23613 provides an in vitro method for determining ribonuclease H activity, which can be used to determine the ability to recruit ribonuclease H. Based on an oligonucleotide having the same base sequence as the test modified oligonucleotide but containing only DNA monomers with phosphorothioate linkages between all monomers in the oligonucleotide, using the methods described in Examples 91 to 95 provided in WO01 / 23613 (incorporated herein by reference), the initial rate is determined in picomoles per liter per minute (pmol / l / min). If the initial rate of reaction of an oligonucleotide with a complementary target nucleic acid sequence is at least 5%, such as at least 10% or more than 20%, of the above reference initial rate, the oligonucleotide is generally considered to be able to recruit ribonuclease H. Recombinant human ribonuclease H1 from Lubio Science GmbH, Lucerne, Switzerland, can be used in determining ribonuclease H activity.

[0254] Gapmer

[0255] The antisense oligonucleotides of the present invention, or continuous nucleotide sequences thereof, can be a gapmer, also known as a gapmer oligonucleotide or gapmer design. Antisense gapmers are commonly used to inhibit target nucleic acids through ribonuclease H-mediated degradation. A gapmer oligonucleotide comprises at least three distinct structural regions, namely a 5'-flank, a gap, and a 3'-flank, in the F-G-F' orientation from 5' to 3'. The "gap" region (G) comprises a continuous DNA nucleotide sequence that enables the oligonucleotide to recruit ribonuclease H. The gap region is flanked on the 5' side by a 5'-flank region (F) containing one or more sugar-modified nucleosides, preferably high-affinity sugar-modified nucleosides, and on the 3' side by a 3'-flank region (F') containing one or more sugar-modified nucleosides, preferably high-affinity sugar-modified nucleosides. One or more of the sugar-modified nucleosides in regions F and F' can enhance the affinity of the oligonucleotide for the target nucleic acid (i.e., they are affinity-enhancing sugar-modified nucleosides). In certain embodiments, one or more of the sugar-modified nucleosides in regions F and F' are 2'-sugar-modified nucleosides, such as high-affinity 2'-sugar modifications, such as independently selected from LNA and 2'-MOE.

[0256] In a gapmer design, the 5' and 3' terminal nucleotides of the gap region are DNA nucleotides and are positioned adjacent to the sugar-modified nucleotides in the 5' (F) or 3' (F') regions, respectively. The flanks can be further defined as having at least one sugar-modified nucleotide at the end farthest from the gap region, i.e., the 5'-end of the 5'-flank and the 3'-end of the 3'-flank.

[0257] The region F-G-F' forms a continuous nucleotide sequence. The antisense oligonucleotides of the present invention, or continuous nucleotide sequences thereof, can comprise a gapmer region of the formula F-G-F'.

[0258] The overall length of the gapmer design F-G-F' can be, for example, from 12 to 32 nucleotides, such as from 13 to 24 nucleotides, such as from 14 to 22 nucleotides, such as from 14 to 17 nucleotides, such as from 16 to 18 nucleotides, such as from 16 to 20 nucleotides.

[0259] For example, the gapmer oligonucleotides of the present invention can be represented by the formula:

[0260] F 1-8 -G 6-16 -F' 2-8 For example

[0261] F 2-8 -G 6-14 -F' 2-8 Such as

[0262] F 3-8 -G 6-14 -F' 2-8

[0263] with the proviso that the overall length of the gapmer region F-G-F’ is at least 10, such as at least 12, such as at least 14 nucleotides.

[0264] In aspects of the invention, the antisense oligonucleotide or a contiguous nucleotide sequence thereof consists of a gapmer of formula 5’-F-G-F’-3’ or comprises a gapmer of formula 5’-F-G-F’-3’, wherein regions F and F’ independently comprise from 1 to 8 nucleosides or consist of from 1 to 8 nucleosides, wherein 2 to 4 are 2’-sugar modified and define the 5’ and 3’ ends of the F and F’ regions, and G is a region between 6 and 16 nucleosides capable of recruiting ribonuclease H.

[0265] Regions F, G and F’ are further defined below and may be incorporated into the F-G-F’ formula.

[0266] Gapmer - Region G

[0267] The gapmer's region G (the gap region) is the region of nucleosides (usually DNA nucleosides) that enables the oligonucleotide to recruit ribonuclease H, such as human ribonuclease H1. Ribonuclease H is a cellular enzyme that recognizes duplexes between DNA and RNA and enzymatically cleaves the RNA molecule. A suitable gapmer may have a gap region (G) of at least 5 or 6 contiguous DNA nucleosides, such as 5 - 16 contiguous DNA nucleosides, such as 6 - 15 contiguous DNA nucleosides, such as 7 - 14 contiguous DNA nucleosides, such as 8 - 12 contiguous DNA nucleosides, such as a length of 8 - 12 contiguous DNA nucleosides. In some embodiments, the gap region G may consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous DNA nucleosides. The cytosine (C) DNA in the gap region may in some cases be methylated, and these residues may either be annotated as 5′-methyl-cytosine ( me C or with e instead of c). Methylation of cytosine DNA in the gap is advantageous if cg dinucleotides are present in the gap to reduce potential toxicity, and this modification has no significant effect on the efficacy of the oligonucleotide. 5’-substituted DNA nucleosides, such as 5’-methyl DNA nucleosides, have been reported for use in DNA gap regions (EP 2 742 136).

[0268] In some embodiments, the gap region G may consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous phosphorothioate-linked DNA nucleosides. In some embodiments, all internucleoside linkages in the gap are phosphorothioate linkages.

[0269] Although traditional nicked bodies have DNA nick regions, there are many examples of modified nucleosides that allow ribonuclease H recruitment when they are used within the nick region. Modified nucleosides that have been reported to be able to recruit ribonuclease H when included within the nick region include, for example, α-L-LNA, C4'-alkylated DNA (such as PCT / EP2009 / 050349 and Vester et al., Bioorg. Med. Chem. Lett. 18 (2008) 2296-2300, both of which are incorporated herein by reference), arabinose-derived nucleosides such as ANA and 2'F-ANA (Mangos et al., 2003 J. AM. CHEM. SOC. 125, 654-661), UNA (unlocked nucleic acid) (as described in Fluiter et al., Mol. Biosyst., 2009, 10, 1039, which is incorporated herein by reference). UNA is an unlocked nucleic acid, typically in which the bond between C2 and C3 of the ribose has been removed, forming an unlocked "sugar" residue. The modified nucleosides used in such nicked bodies can be nucleosides that adopt a 2'-endo (DNA-like) structure when introduced into the nick region, i.e., a modification that allows ribonuclease H recruitment. In some embodiments, the DNA nick region (G) described herein can optionally contain 1 to 3 sugar-modified nucleosides that adopt a 2'-endo (DNA-like) structure when introduced into the nick region.

[0270] Region G - "Gap - breaker)"

[0271] Alternatively, there are many reports of inserting modified nucleosides that impart a 3'-endo conformation to the nick region of a nicked body while retaining some ribonuclease H activity. Such nicked bodies having a nick region containing one or more 3'-endo modified nucleosides are referred to as "gap - breaker" or "gap -A "nicked body" (disrupted), see, for example, WO2013 / 022984. The nick-interrupter oligonucleotide retains a sufficient region of DNA nucleotides within the nick region to allow recruitment of ribonuclease H. The ability of the nick-interrupter oligonucleotide to be designed to recruit ribonuclease H is generally sequence- and even compound-specific - see Rukov et al., 2015 Nucl. Acids Res. Vol. 43 pp. 8476-8487, which discloses "nick-interrupter" oligonucleotides that recruit ribonuclease H, which in some cases provides more specific cleavage of the target RNA. Modified nucleotides used within the nick region of the nick-interrupter oligonucleotide can be, for example, modified nucleotides that confer a 3'-endo conformation, such as 2'-O-methyl (OMe) or 2'-O-MOE (MOE) nucleotides, or β-D LNA nucleotides (the bridge between C2' and C4' of the ribose ring of the nucleotide is in the β conformation), such as β-D-oxy-LNA or ScET nucleotides.

[0272] Similar to the nicked bodies containing region G described above, the nick region of the nick-interrupter or nick-disrupting interrupter nicked body has DNA nucleotides at the 5' end of the nick (adjacent to the 3' nucleotide of region F) and DNA nucleotides at the 3' end of the nick (adjacent to the 5' nucleotide of region F'). Nicked bodies containing interrupted nicks generally retain a region of at least 3 or 4 consecutive DNA nucleotides at the 5' or 3' end of the nick region.

[0273] Exemplary designs of the nick-interrupter oligonucleotide include

[0274] F 1-8 -[D 3-4 -E 1- D 3-4 _F’ 1-8

[0275] F 1-8 -[D 1-4 -E 1- D 3-4 -F’ 1-8

[0276] F 1-8 -[D 34 -E 1 -D 1-4 -F’ 1-8

[0277] where region G is within the brackets [D n -E r -D mwherein D is a contiguous sequence of DNA nucleotides, E is a modified nucleotide (a nick breaker or a nick breaking nucleotide), and F and F’ are flanking regions as defined herein, and provided that the overall length of the nicked body region F-G-F’ is at least 12, such as a length of at least 14 nucleotides.

[0278] In some embodiments, the region G of the nicked breaking nicked body comprises at least 6 DNA nucleotides, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 DNA nucleotides. As described above, the DNA nucleotides may be contiguous or may optionally be interspersed with one or more modified nucleotides, provided that the nicked region G is capable of mediating ribonuclease H recruitment.

[0279] Nicked body - flanking regions, F and F’

[0280] Region F is adjacent to the 5’ DNA nucleotide of region G. The most 3’ nucleotide of region F is a sugar modified nucleotide, such as a high affinity sugar modified nucleotide, for example a 2’ substituted nucleotide, such as a MOE nucleotide or a LNA nucleotide.

[0281] Region F’ is adjacent to the 3’ DNA nucleotide of region G. The most 5’ nucleotide of region F’ is a sugar modified nucleotide, such as a high affinity sugar modified nucleotide, for example a 2’ substituted nucleotide, such as a MOE nucleotide or a LNA nucleotide.

[0282] Region F has a length of 1 - 8 contiguous nucleotides, such as a length of 2 - 6, such as 3 - 4 contiguous nucleotides. Advantageously, the most 5’ nucleotide of region F is a sugar modified nucleotide. In some embodiments, the two most 5’ nucleotides of region F are sugar modified nucleotides. In some embodiments, the most 5’ nucleotide of region F is a LNA nucleotide. In some embodiments, the two most 5’ nucleotides of region F are LNA nucleotides. In some embodiments, the two most 5’ nucleotides of region F are 2’ substituted nucleotides, such as two 3’ MOE nucleotides. In some embodiments, the most 5’ nucleotide of region F is a 2’ substituted nucleotide, such as a MOE nucleotide.

[0283] Region F’ has a length of 2 - 8 contiguous nucleotides, such as a length of 3 - 6, such as 4 - 5 contiguous nucleotides. Advantageously, the most 3’ nucleotide of region F’ in an embodiment is a sugar modified nucleotide. In some embodiments, the two most 3’ nucleotides of region F’ are sugar modified nucleotides. In some embodiments, the two most 3’ nucleotides of region F’ are LNA nucleotides. In some embodiments, the most 3’ nucleotide of region F’ is a LNA nucleotide. In some embodiments, the two most 3’ nucleotides of region F’ are 2’ substituted nucleotides, such as two 3’ MOE nucleotides. In some embodiments, the most 3’ nucleotide of region F’ is a 2’ substituted nucleotide, such as a MOE nucleotide.

[0284] It should be noted that when the length of region F or F' is one, it is advantageously an LNA nucleoside.

[0285] In some embodiments, regions F and F' independently consist of a contiguous sequence of sugar-modified nucleosides or contain a contiguous sequence of sugar-modified nucleosides. In some embodiments, the sugar-modified nucleosides of region F may independently be selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units, and 2'-fluoro-ANA units.

[0286] In some embodiments, regions F and F' independently contain both LNA and 2'-substituted modified nucleosides (mixed flank design).

[0287] In some embodiments, regions F and F' consist of only one type of sugar-modified nucleoside, such as only MOE or only β-D-oxy-LNA or only ScET. This design is also referred to as a homogeneous flank or homogeneous gapmer design.

[0288] In some embodiments, all of the nucleosides of region F or F', or F and F' are LNA nucleosides, such as independently selected from β-D-oxy-LNA, ENA, or ScET nucleosides. In some embodiments, region F consists of 1-5, such as 2-4, such as 3-4, such as 1, 2, 3, 4, or 5 contiguous LNA nucleosides. In some embodiments, all of the nucleosides of regions F and F' are β-D-oxy-LNA nucleosides.

[0289] In some embodiments, all of the nucleosides of region F or F', or F and F' are 2'-substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments, region F may consist of 1, 2, 3, 4, 5, 6, 7, or 8 contiguous OMe or MOE nucleosides. In some embodiments, only one flank region may consist of 2'-substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments, the 5'(F) flank region consists of 2'-substituted nucleosides, such as OMe or MOE nucleosides, while the 3'(F') flank region contains at least one LNA nucleoside, such as a β-D-oxy-LNA nucleoside or a cET nucleoside. In some embodiments, the 3'(F') flank region consists of 2'-substituted nucleosides, such as OMe or MOE nucleosides, while the 5'(F) flank region contains at least one LNA nucleoside, such as a β-D-oxy-LNA nucleoside or a cET nucleoside.

[0290] In some embodiments, all of the modified nucleosides in regions F and F' are LNA nucleosides, such as independently selected from β-D-oxy-LNA, ENA, or ScET nucleosides, where region F or F′, or F and F' may optionally contain DNA nucleosides (alternating flanks, see definitions thereof). In some embodiments, all of the modified nucleosides in regions F and F' are β-D-oxy-LNA nucleosides, where region F or F′, or F and F' may optionally contain DNA nucleosides (alternating flanks, see definitions thereof).

[0291] In some embodiments, the 5'-most and 3'-most nucleosides of regions F and F' are LNA nucleosides, such as β-D-oxy-LNA nucleosides or ScET nucleosides.

[0292] In some embodiments, the internucleoside bond located between region F and region G is a phosphorothioate internucleoside bond. In some embodiments, the internucleoside bond located between region F' and region G is a phosphorothioate internucleoside bond. In some embodiments, the internucleoside bond between the nucleosides of region F or F′, F and F' is a phosphorothioate internucleoside bond.

[0293] LNA gapmer

[0294] An LNA gapmer refers to a gapmer in which either or both of regions F and F' contain or have LNA nucleosides. A β-D-oxy gapmer refers to a gapmer in which either or both of regions F and F' contain or have β-D-oxy-LNA nucleosides.

[0295] In certain embodiments, the LNA gapmer has the following formula: [LNA] 1-5 -[region G]-[LNA] 1-5 , where region G has the definition as defined in the definition of the gapmer region G as described above.

[0296] In one embodiment, the LNA gapmer has the formula [LNA] 4 -[region G] 10-12 -[LNA] 4 and so on.

[0297] MOE gapmer

[0298] A MOE gapmer is a gapmer in which regions F and F' are composed of MOE nucleosides. In certain embodiments, the MOE gapmer is designed as [MOE] 1-8 -[region G] 5-16 -[MOE] 1-8 , such as [MOE] 2-7 -[region G] 6-14 -[MOE]2-7 , such as [MOE] 3-6 - [Region G] 8-12 - [MOE] 3-6 , wherein Region G has the definition as defined in the described gapmer definition. MOE gapmers having a 5 - 10 - 5 design (MOE - DNA - MOE) have been widely used in the art.

[0299] Hybrid wing gapmer

[0300] A hybrid wing gapmer is an LNA gapmer, wherein one or both of Regions F and F' contain 2'-substituted nucleosides, such as 2'-substituted nucleosides independently selected from the group consisting of 2'-O-alkyl - RNA units, 2'-O-methyl - RNA, 2'-amino - DNA units, 2'-fluoro - DNA units, 2'-alkoxy - RNA, MOE units, arabinonucleic acid (ANA) units, and 2'-fluoro - ANA units, such as MOE nucleosides. In certain embodiments, at least one of Regions F and F' or both Regions F and F' contain at least one LNA nucleoside, and the remaining nucleosides of Regions F and F' are independently selected from the group consisting of MOE and LNA. In certain embodiments, at least one of Regions F or F' or both Regions F and F' contain at least two LNA nucleosides, and the remaining nucleosides of Regions F and F' are independently selected from the group consisting of MOE and LNA. In certain embodiments of the hybrid wing, one or both of Regions F and F' may further contain one or more DNA nucleosides.

[0301] The hybrid wing gapmer design has been disclosed in WO2008 / 049085 and WO2012 / 109395, both of which are incorporated herein by reference.

[0302] Alternating flank gapmer

[0303] The flank region may contain both LNA and DNA nucleosides and is referred to as "alternating flank" because it contains an alternating motif of LNA - DNA - LNA nucleosides. A gapmer containing such an alternating flank is called an "alternating flank gapmer". "Alternative flank gapmer" refers to an LNA gapmer oligonucleotide, wherein at least one flank (F or F') contains DNA in addition to LNA nucleosides. In certain embodiments, at least one of Regions F or F' or both contain both LNA nucleosides and DNA nucleosides. In such embodiments, the flank region F or F', or both F and F', contains at least three nucleosides, wherein the 5' and 3' majority nucleosides of the F and / or F' regions are LNA nucleosides.

[0304] The alternating flank LNA gapmer is disclosed in WO2016 / 127002.

[0305] An alternating flank region may contain up to 3 consecutive DNA nucleosides, such as 1 to 2 or 1 or 2 or 3 consecutive DNA nucleosides.

[0306] The alternating flank may be annotated as a series of integers representing the number of LNA nucleosides (L), followed by the number of DNA nucleosides (D), such as

[0307] [L] 1-3 -[D] 1-4 -[L] 1-3

[0308] [L] 1-2 -[D] 1-2 -[L] 1-2 -[D] 1-2 -[L] 1-2

[0309] In oligonucleotide design, these are typically represented as numbers such that 2-2-1 represents 5’[L] 2 -[D] 2 -[L] 3’, and 1-1-1-1-1 represents 5’[L]-[D]-[L]-[D]-[L] 3′. The length of the flanks (regions F and F′) in an oligonucleotide with alternating flanks can independently be 3 to 10 nucleosides, such as 4 to 8, such as 5 to 6 nucleosides, such as 4, 5, 6, or 7 modified nucleosides. In some embodiments, only one flank in a gapmer oligonucleotide is of the alternating type while the other flank consists of LNA nucleotides. It may be advantageous to have at least two LNA nucleosides at the 3’ end of the 3’ flank (F’) to confer additional exonuclease resistance. In one embodiment, the flanks in the alternating flank gapmer have 3 to 5 of 5 to 8 nucleosides in total length being LNA nucleosides. Some examples of oligonucleotides with alternating flanks are:

[0310] [L] 1-5 -[D] 1-4 -[L] 1-3 -[G] 5-16 -[L] 2-6

[0311] [L] 1-2 -[D] 2-3 -[L] 3-4 --[G] 5-7 -[L] 1-2 -[D] 2-3 -[L] 2-3

[0312] [L] 1-2 -[D] 1-2-[L] 1-2 -[D] 1-2 -[L] 1-2 -[G] 5-16 -[L] 1-2 -[D] 1-3 -[L] 2-4

[0313] [L] 1-5 -[G] 5-16 -[L]-[D]-[L]-[D]-[L] 2

[0314] [L] 4 -[G] 6-10 -[L]-[D] 3 -[L] 2

[0315] However, the overall length of the nicked body is at least 12, such as at least 14 nucleotides.

[0316] Region D' or D" in the oligonucleotide

[0317] In certain embodiments, the oligonucleotides of the invention may comprise or have the continuous nucleotide sequence of the oligonucleotide that is complementary to the target nucleic acid, the continuous nucleotide sequence being, for example, the nicked body F-G-F' and further 5' and / or 3' nucleosides. The further 5' and / or 3' nucleosides may or may not be fully complementary to the target nucleic acid. These further 5' and / or 3' nucleosides may be referred to herein as regions D' and D".

[0318] The addition of region D' or D" can be used to link the continuous nucleotide sequence, such as the nicked body, to a conjugate moiety or another functional group. When used to conjugate the continuous nucleotide sequence to a conjugate moiety, it can serve as a bio-cleavable linker. Alternatively, it can be used to provide exonuclease protection or to facilitate synthesis or manufacture.

[0319] Regions D' and D" can be attached to the 5' end of region F or the 3' end of region F', respectively, to produce the following design: D'-F-G-F', F-G-F'-D", or

[0320] D'-F-G-F'-D". In this example, F-G-F' is the nicked body portion of the oligonucleotide, and regions D' or D" constitute a separate portion of the oligonucleotide.

[0321] Region D' or D" may independently contain or have 1, 2, 3, 4, or 5 additional nucleotides, which may or may not be complementary to the target nucleic acid. The nucleotides flanking region F or F' are not sugar-modified nucleotides, such as DNA or RNA or base-modified versions thereof. Region D' or D" may serve as a nuclease-susceptible biodegradable linker (see linker definition). In certain embodiments, the additional 5' and / or 3' terminal nucleotides are linked by a phosphodiester bond and are DNA or RNA. Nucleotide-based biodegradable linkers suitable for region D' or D" may be referred to the disclosure of WO2014 / 076195 and may include, for example, phosphodiester-linked DNA dinucleotides. The use of biodegradable linkers in polyoligonucleotide constructs may be referred to the disclosure of WO2015 / 113922, in which case it is used to link multiple antisense constructs (such as gapmer regions) in a single oligonucleotide.

[0322] In one embodiment, the oligonucleotide of the present invention, in addition to comprising a continuous nucleotide sequence constituting the gapmer, further comprises region D' and / or D".

[0323] In certain embodiments, the oligonucleotide of the present invention may be represented by the following formula:

[0324] F-G-F'; especially F 2-8 -G 6-16 -F' 2-8

[0325] D'-F-G-F', especially D' 2-3 -F 1-8 -G 6-16 -F' 2-8

[0326] F-G-F'-D", especially F 2-8 -G 6-16 -F' 2-8 - D" 1-3

[0327] D'-F-G-F'-D", especially D’ 1-3 -F 2-8 -G 6-16 -F’ 2-8 - D" 1-3

[0328] In certain embodiments, the internucleoside bond located between region D' and region F is a phosphodiester bond. In certain embodiments, the internucleoside bond located between region F' and region D" is a phosphodiester bond.

[0329] Conjugate

[0330] As used herein, the term conjugate refers to an oligonucleotide covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region).

[0331] The conjugation of the oligonucleotides of the present invention to one or more non-nucleotide moieties can improve the pharmacology of the oligonucleotides, for example, by affecting the activity, cellular distribution, cellular uptake, or stability of the oligonucleotides. In certain embodiments, the conjugate moiety modulates or enhances the pharmacodynamic properties of the oligonucleotide by improving the cellular distribution, bioavailability, metabolism, excretion, permeability, and / or cellular uptake of the oligonucleotide. Specifically, the conjugate targets the oligonucleotide to a specific organ, tissue, or cell type and thereby enhances the effect of the oligonucleotide in that organ, tissue, or cell type. At the same time, the conjugate can reduce the activity of the oligonucleotide in non-target cell types, tissues, or organs, such as off-target activity or activity in non-target cell types, tissues, or organs.

[0332] Oligonucleotide conjugates and their synthesis have also been reported in Manoharan's Antisense Drug Technology, Principles, Strategies, and Applications, S.T. Crooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan's Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.

[0333] In one embodiment, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of carbohydrates (such as GalNAc), cell surface receptor ligands, active pharmaceutical ingredients, hormones, lipophilic substances, polymers, proteins, peptides, toxins (such as bacterial toxins), vitamins, viral proteins (such as capsids), or combinations thereof.

[0334] In certain embodiments, the conjugate is an antibody or antibody fragment having specific affinity for the transferrin receptor, such as that disclosed in WO 2012 / 143379, which is incorporated herein by reference. In certain embodiments, the non-nucleotide moiety is an antibody or antibody fragment, such as an antibody or antibody fragment that facilitates drug delivery across the blood-brain barrier, particularly an antibody or antibody fragment that targets the transferrin receptor.

[0335] Linker

[0336] A bond or linker is a connection between two atoms that serves to link one chemical group or moiety of interest to another chemical group or moiety of interest via one or more covalent bonds. The conjugate moiety can be attached directly or via a linking moiety (e.g., a linker or tether) to the oligonucleotide. The linker can covalently connect a third region, e.g., the conjugate moiety (region C), to a first region, e.g., an oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A).

[0337] In certain embodiments of the invention, the conjugate or oligonucleotide conjugate of the invention can optionally comprise a linker region (second region or region B and / or region Y) that is located between the oligonucleotide or contiguous nucleotide sequence (region A or first region) complementary to the target nucleic acid and the conjugate moiety (region C or third region).

[0338] Region B refers to a biodegradable linker that contains or has a physiologically labile bond that becomes cleavable under normal or analogous conditions in a mammalian body. Conditions for the biodegradable linker to undergo chemical transformation (e.g., cleavage) include chemical conditions such as pH, temperature, oxidation or reduction conditions or agents, and salt concentrations that are normal or analogous to those present in mammalian cells. Conditions in mammalian cells also include enzyme activities that are typically present in mammalian cells, such as the activities of proteases or hydrolases or nucleases. In one embodiment, the biodegradable linker is susceptible to cleavage by S1 nuclease. In a preferred embodiment, the nuclease-susceptible linker contains between 1 and 10 nucleosides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, more preferably 2 to 6 nucleosides, and most preferably 2 to 4 linked nucleosides, the linked nucleosides containing at least two consecutive phosphodiester bonds, such as at least 3, 4, or 5 consecutive phosphodiester bonds. The nucleoside is preferably DNA or RNA. For a detailed description of the phosphodiester containing the biodegradable linker, see WO 2014 / 076195 (incorporated herein by reference).

[0339] Region Y refers to a linker that is not necessarily biodegradable but whose main function is to covalently link a conjugate moiety (region C or the third region) to an oligonucleotide (region A or the first region). The region Y linker can include a chain structure or an oligomer of repeating units such as ethylene glycol, amino acid units, or aminoalkyl groups. The oligonucleotide conjugate of the present invention can be constructed from the following regional elements: A-C, A-B-C, A-B-Y-C, A-Y-B-C, or A-Y-C. In certain embodiments, the linker (region Y) is aminoalkyl, such as a C2 to C36 aminoalkyl group, including, for example, a C6 to C12 aminoalkyl group. In a preferred embodiment, the linker (region Y) is a C6 aminoalkyl group.

[0340] Treatment

[0341] As used herein, the term "treatment" refers to treating an existing disease (such as the diseases or disorders mentioned herein), or preventing a disease, that is, prophylaxis. Thus, it should be understood that treatment as referred to herein, in certain embodiments, is of a prophylactic nature.

[0342] In some embodiments, a patient diagnosed with a neurological disorder is treated, the neurological disorder being selected from neurodegenerative diseases, including Tau deposition disorders, Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD), and FTD associated with Parkinsonism linked to chromosome 17 (FTDP-17), Pick's disease (PiD), argyrophilic grain disease (AGD), tangle-predominant senile dementia (TPSD), primary age-related Tau deposition disorder (PART), Down syndrome, and Guam lytico-bodig disease. Upregulation of pathological Tau is associated with infantile Tau deposition disorders, including hemimegalencephaly (HME), tuberous sclerosis complex; focal cortical dysplasia type 2b; and ganglioglioma. In addition, abnormal Tau expression and / or function may also be associated with other diseases, such as Hallervorden-Spatz syndrome, also known as neurodegeneration with brain iron accumulation type 1 (NBIA1), gangliocytoma, and subacute sclerosing panencephalitis. Tau can also play a role in seizure disorders (such as epilepsy), network dysfunction (such as depression), and movement disorders (such as Parkinson's disease). Detailed Description

[0343] The oligonucleotide of the present invention

[0344] The present invention relates to oligonucleotides capable of modulating the expression of Tau, such as inhibiting (downregulating) Tau expression. The modulation is achieved by hybridizing with a target nucleic acid encoding Tau. The target nucleic acid can be a mammalian MAPT mRNA sequence, such as a sequence selected from the group consisting of SEQ ID NO: 1 and 2.

[0345] The oligonucleotides of the present invention are antisense oligonucleotides that target MAPT, resulting in a decrease in Tau expression.

[0346] In certain embodiments, the antisense oligonucleotides of the present invention are capable of modulating the target by inhibiting or downregulating its expression. Preferably, the above modulation can produce at least 20% expression inhibition compared to the normal expression level of the target, more preferably at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% expression inhibition compared to the normal expression level. In some embodiments, according to in vitro experiments, after using 5 μM oligonucleotides on primary neuronal cells, the oligonucleotides of the present invention can inhibit the expression level of Tau mRNA by at least 60% or 70%. In some embodiments, according to in vitro experiments, after using 0.5 μM oligonucleotides on primary neuronal cells, the compounds of the present invention can inhibit the expression level of Tau protein by at least 50%. Suitably, assays for measuring Tau RNA or protein inhibition are provided in the examples (e.g., Example 1 and Example 3). Target modulation is triggered by hybridization between the continuous nucleotide sequence of the oligonucleotide and the target nucleic acid. In some embodiments, the oligonucleotides of the present invention contain mismatches between the oligonucleotide and the target nucleic acid. Despite the mismatches, hybridization with the target nucleic acid can still be sufficient to show the desired modulation of Tau expression. The reduced binding affinity caused by the mismatches can be advantageously compensated for by increasing the number of nucleotides in the oligonucleotide and / or increasing the number of modified nucleosides that can increase the binding affinity to the target, such as 2'-sugar modified nucleosides present within the oligonucleotide sequence, including LNA.

[0347] One aspect of the present invention relates to antisense oligonucleotides comprising a continuous nucleotide sequence of at least 10 nucleotides, which has at least 90% complementarity with SEQ ID NO: 3, 4, or 5.

[0348] In certain embodiments, the oligonucleotide comprises a continuous sequence of 10 to 30 nucleotides that is at least 90% complementary, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, or 100% complementary, to a region of the target nucleic acid or target sequence.

[0349] Advantageously, the oligonucleotide of the present invention or its consecutive nucleotide sequence is completely complementary (100% complementary) to the region of the target nucleic acid, or, in some embodiments, one or two sets of mismatches may exist between the oligonucleotide and the target nucleic acid.

[0350] In some embodiments, the oligonucleotide comprises a consecutive nucleotide sequence having a length of 10 to 30 nucleotides, which is at least 90% complementary, such as completely (or 100%) complementary, to the consecutive nucleotides within positions 12051 to 12111, 39562 to 39593, or 72837 to 72940 of SEQ ID NO: 1.

[0351] In some embodiments, the oligonucleotide sequence is 100% complementary to the corresponding target nucleic acid regions present in SEQ ID NO: 1 and SEQ ID NO: 2.

[0352] It is advantageous if the antisense oligonucleotide is complementary to a target sequence selected from one of the regions listed in Table 4. In some embodiments, the consecutive nucleotide sequence of the antisense oligonucleotide is at least 90% complementary, such as completely complementary, to the selected target sequence of R1-R2254 (Table 4). In some embodiments, the oligonucleotide sequence is 100% complementary to R_223, R_738, or R_1298 (see Table 4).

[0353] In some embodiments, the oligonucleotide or consecutive nucleotide sequence is 90% complementary, such as completely complementary, to a target nucleic acid region selected from the group consisting of positions 12051-12111 of SEQ ID NO: 1, such as positions 12051-12079, 12085-12111, or 12060-12078 of SEQ ID NO: 1.

[0354] In another embodiment, the oligonucleotide or consecutive nucleotide sequence is 90% complementary, such as completely complementary, to a target nucleic acid region selected from the group consisting of positions 39562-39593 of SEQ ID NO: 1, such as positions 39573-39592 of SEQ ID NO: 1.

[0355] In another embodiment, the oligonucleotide or consecutive nucleotide sequence is 90% complementary, such as completely complementary, to a target nucleic acid region selected from the group consisting of positions 72837-72940 of SEQ ID NO: 1, such as positions 72861-72891 or 72862-72890 of SEQ ID NO: 1.

[0356] In some embodiments, the oligonucleotide comprises a contiguous nucleotide sequence that is 16 to 22 nucleotides in length, such as 16 to 20 nucleotides, and is 100% complementary to the contiguous nucleotides within positions 12060 to 12078 or 39573 to 39592 or 72862 to 72890 of SEQ ID NO: 1.

[0357] In certain embodiments, the oligonucleotide of the present invention comprises or has 10 to 35 nucleotides in length, for example 10 to 30, such as 11 to 25, such as 12 to 22, such as 14 to 20 or 14 to 18 contiguous nucleotides. In one embodiment, the oligonucleotide comprises or has 16 to 22 nucleotides in length. In a preferred embodiment, the oligonucleotide comprises or has 16 to 20 nucleotides in length.

[0358] In certain embodiments, the oligonucleotide or its contiguous nucleotide sequence comprises or has 22 or fewer nucleotides, such as 20 or fewer nucleotides, such as 16, 17, 18, 19 or 20 nucleotides. It should be understood that all ranges given herein include the range endpoints. Accordingly, if an oligonucleotide is described herein as comprising from 10 to 30 nucleotides, both 10 and 30 nucleotides are included.

[0359] In certain embodiments, the contiguous nucleotide sequence comprises or has 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides in length. In a preferred embodiment, the oligonucleotide comprises or consists of 16, 17, 18, 19 or 20 nucleotides in length.

[0360] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises or consists of the sequences listed in Table 5 (Materials and Methods section).

[0361] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of nucleotides that are 10 to 30 in length and have at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 6 to 65 (motif sequences listed in Table 5).

[0362] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of: nucleotides that are 10 to 30 in length and have at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 9, 11, 49, 53, 56, and 62 (motif sequences listed in Table 5).

[0363] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of: nucleotides that are 10 to 30 in length and have at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 6 to 37 (motif sequences listed in Table 5).

[0364] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of: nucleotides that are 10 to 30 in length and have at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 9 or 11 (motif sequences listed in Table 5).

[0365] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of: nucleotides that are 10 to 30 in length and have at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 38 to 51 (motif sequences listed in Table 5).

[0366] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of: nucleotides that are 10 to 30 in length and have at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 49 or 51 (motif sequences listed in Table 5).

[0367] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of: nucleotides that are 10 to 30 in length and have at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 52 to 65 (motif sequences listed in Table 5).

[0368] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of: nucleotides that are 10 to 30 in length and have at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 56 or 62 (motif sequences listed in Table 5).

[0369] It should be understood that a modified contiguous nucleobase sequence (motif sequence) can be modified, for example, to increase nuclease resistance and / or binding affinity to a target nucleic acid.

[0370] The pattern of incorporating modified nucleosides (such as high-affinity modified nucleosides) into an oligonucleotide sequence is generally referred to as oligonucleotide design.

[0371] The oligonucleotide designs of the present invention have modified nucleosides and DNA nucleosides. Advantageously, high-affinity modified nucleosides are used.

[0372] In one embodiment, the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, or at least 16 modified nucleosides. In one embodiment, the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides. Suitable modifications are described in the "Definitions" sections of "Modified Nucleosides", "High-Affinity Modified Nucleosides", "Sugar Modifications", "2'-Sugar Modifications", and Locked Nucleic Acids (LNAs).

[0373] In one embodiment, the oligonucleotide comprises one or more sugar-modified nucleosides, such as 2'-sugar-modified nucleosides. Preferably, the oligonucleotides of the present invention comprise one or more 2'-sugar-modified nucleosides, which are independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabinonucleic acid (ANA), 2'-fluoro-ANA, and LNA nucleosides. It is advantageous if one or more of the modified nucleosides are locked nucleic acids (LNAs).

[0374] In a further embodiment, the oligonucleotide comprises at least one modified internucleoside bond. Suitable internucleoside modifications are described in the "Definitions" section under "Modified Internucleoside Bonds". Advantageously, at least 75%, such as 80%, such as all of the internucleoside bonds within the contiguous nucleotide sequence are phosphorothioate or boranophosphate internucleoside bonds. In some embodiments, all of the internucleotide bonds in the contiguous sequence of the oligonucleotide are phosphorothioate bonds.

[0375] In some embodiments, the oligonucleotides of the present invention comprise at least one LNA nucleoside, such as 1, 2, 3, 4, 5, 6, 7, or 8 LNA nucleosides, such as 2 to 6 LNA nucleosides, such as 3 to 7 LNA nucleosides, 4 to 8 LNA nucleosides, or 3, 4, 5, 6, 7, or 8 LNA nucleosides. In some embodiments, at least 75% of the modified nucleosides in the oligonucleotide are LNA nucleosides, for example 80%, for example 85%, for example 90% of the modified nucleosides are LNA nucleosides, especially β-D-oxy-LNA or ScET. In yet further embodiments, all of the modified nucleosides in the oligonucleotide are LNA nucleosides. In further embodiments, the oligonucleotide may comprise β-D-oxy-LNA and one or more of the following LNA nucleosides: thio-LNA, amino-LNA, oxy-LNA, ScET, and / or ENA, in β-D or α-L configuration or a combination thereof. In further embodiments, all LNA cytosine units are 5-methyl-cytosine. Advantageously for nuclease stability, the oligonucleotide or contiguous nucleotide sequence has at least 1 LNA nucleoside at the 5' end of the nucleotide sequence and at least 2 LNA nucleosides at the 3' end of the nucleotide sequence.

[0376] In one embodiment of the present invention, the oligonucleotides of the present invention are capable of recruiting ribonuclease H.

[0377] In the present invention, a favorable structural design is the gapmer design as described in the "Definitions" section, such as "gapmer", "LNA gapmer", "MOE gapmer", and "hybrid wing gapmer", "alternating flank gapmer". The gapmer design includes gapmers with uniform flanks, hybrid wing flanks, alternating flanks, and gap breaker designs. In the present invention, it is favorable if the oligonucleotide of the present invention is a gapmer with an F-G-F' design, especially a gapmer of the formula 5'-F-G-F'-3', where regions F and F' independently comprise 1 to 8 nucleosides, where 2 to 5 are 2'-sugar modified and define the 5' and 3' ends of the F and F' regions, and G is a region between 6 and 16 nucleosides capable of recruiting ribonuclease H, such as a region comprising 6 to 16 DNA nucleosides.

[0378] In some embodiments, the gapmer is an LNA gapmer.

[0379] In some embodiments of the present invention, the LNA gapmer is selected from the following uniform flank designs: 4-10-4, 3-11-4, 4-11-4, 4-12-4, or 4-14-2.

[0380] In some embodiments of the present invention, the LNA nick system is selected from the following alternating flank designs: 3-1-3-10-2, 1-3-4-6-1-3-2, 1-2-1-2-2-8-4, or 3-3-1-8-2-1-2.

[0381] Table 5 (in the Materials and Methods section) lists the preferred designs for each motif sequence.

[0382] In all cases, the F-G-F' design may further include regions D' and / or D", as described in the "Definition" section under "Region D' or D" in oligonucleotides". In some embodiments, the oligonucleotides of the present invention have 1, 2, or 3 phosphodiester-linked nucleoside units, such as DNA units, at the 5' or 3' end of the nick region.

[0383] For some embodiments of the present invention, the oligonucleotide is selected from the group of oligonucleotide compounds having the following CMP ID NO: 6_1; 7_1; 8_1; 9_1; 9_2; 9_3; 9_4; 9_5; 9_6; 9_7; 9_8; 9_9; 9_10; 9_11; 9_12; 9_13; 9_14; 9_15; 9_16; 9_17; 9_18; 9_19; 9_20; 9_21; 9_22; 9_23; 9_24; 9_25; 9_26; 9_27; 9_28; 9_29; 9_30; 9_31; 9_32; 9_33; 9_34; 9_35; 9_36; 9_37; 9_38; 9_39; 9_40; 9_41; 9_42; 9_43; 9_44; 9_45; 9_46; 9_47; 9_48; 9_49; 9_50; 9_51; 9_52; 9_53; 9_54; 9_55; 9_56; 9_57; 9_58; 9_59; 9_60; 9_61; 9_62; 9_63; 9_64; 9_65; 9_66; 9_67; 9_68; 9_69; 9_70; 9_71; 9_72; 9_73; 9_74; 9_75; 9_76; 9_77; 9_78; 9_79; 9_80; 9_81; 9_82; 9_83; 9_84; 9_85; 9_86; 9_87; 9_88; 9_89; 9_90; 9_91; 9_92; 9_93; 9_94; 9_95; 9_96; 9_97; 9_98; 9_99; 9_100; 9_101; 9_102; 9_103; 9_104; 9_105; 9_106; 10_1; 10_2; 10_3; 10_4; 10_5; 10_6; 10_7; 10_8; 10_9; 10_10; 10_11; 10_12; 10_13; 1_0_14; 10_15; 10_16; 10_17; 10_18; 10_19; 10_20; 10_21; 10_22; 10_23; 10_24; 10_25; 10_26; 10_27; 10_28; 10_29; 10_30; 10_31; 10_32; 10_33; 10_34; 10_35; 10_36; 10_37; 10_38; 10_39; 10_40; 10_41; 10_42; 10_43; 10_44; 10_45; 10_46; 10_47; 10_48; 10_49; 10_50; 10_51; 10_52; 10_53; 10_54; 10_55; 10_56; 10_57; 10_58; 10_59; 10_60; 10_61; 10_62; 10_63; 10_64; 10_65; 10_66; 10_67; 10_68; 10_69; 10_70;10_71;10_72;10_73;10_74;10_75;10_76;10_77;10_78;10_79;10_80;10_81;10_82;10_83;10_84;10_85;10_86;10_87;10_88;10_89;11_1;12_1;13_1;14_1;151;16_1;17_1;18_1;19_1;20_1;21_1;22_1;23_1;24_1;24_2;24_3;24_4;24_5;24_6;24_7;24_8;24_9;24_10;24_11;24_12;24_13;24_14;24_15;24_16;24_17;24_18;24_19;24_20;24_21;24_22;24_23;24_24;24_25;24_26;24_27;24_28;24_29;24_30;24_31;24_32;24_33;24_34;24_35;24_36;24_37;24_38;24_39;24_40;24_41;24_42;24_43;24_44;24_45;24_46;24_47;24_48;24_49;24_50;24_51;24_52;24_53;24_54;24_55;24_56;24_57;24_58;24_59;24_60;24_61;24_62;25_1;25_2;25_3;25_4;25_5;25_6;25_7;25_8;25_9;25_10;25_11;25_12;25_13;25_14;25_15;25_16;25_17;25_18;25_19;25_20;25_21;25_22;25_23;25_24;25_25;25_26;25_27;25_28;25_29;25_30;25_31;25_32;25_33;25_34;25_35;25_36;25_37;25_38;25_39;25_40;25_41;25_42;25_43;26_1;26_2;26_3;26_4;26_5;26_6;26_7;26_8;26_9;26_10;26_11;26_12;26_13;26_14;26_15;26_16;26_17;26_18;26_19;26_20;26_21;26_22;26_23;26_24;26_25;26_26;26_27;26_28;26_29;26_30;26_31;27_1;28_1;28_2;28_3;28_4;28_5;28_6;28_7;28_8;28_9;28_10;28_11;28_12;28_13;28_14;28_15;28_16;28_17;28_18;28_19;28_20;28_21;28_22;28_23;28_24;28_25;28_26;28_27;28_28;28_29;28_30;28_31;28_32;28_33;29_1;29_2;29_3;29_4;29_5;29_6;29_7;29_8;29_9;29_10;29_11;29_12;29_13;29_14;30_1;30_2;30_3;30_4;30_5;30_6;30_7;30_8;30_9;30_10;30_11;30_12;30_13;30_14;30_15;30_16;30_17;30_18;30_19;30_20;30_21;30_22;30_23;30_24;30_25;31_1;31_2;31_3;32_1;32_2;32_3;32_4;32_5;32_6;32_7;32_8;32_9;32_10;32_11;32_12;32_13;32_14;32_15;32_16;32_17;32_18;32_19;32_20;32_21;32_22;32_23;32_24;32_25;32_26;32_27;32_28;32_29;32_30;32_31;32_32;32_33;32_34;32_35;32_36;32_37;32_38;32_39;32_40;32_41;32_42;32_43;32_44;32_45;32_46;32_47;32_48;32_49;32_50;32_51;33_1;33_2;33_3;33_4;33_5;33_6;33_7;33_8;33_9;33_10;33_11;33_12;33_13;33_14;33_15;33_16;33_17;33_18;33_19;33_20;33_21;33_22;33_23;33_24;33_25;33_26;33_27;33_28;33_29;33_30;33_31;33_32;33_33;34_1;35_1;35_2;35_3;36_1;37_1;38_1;39_1;40_1;41_1;42_1;43_1;44_1;45_1;46_1;47_1;48_1;49_1;49_2;49_3;49_4;49_5;49_6;49_7;49_8;49_9;49_10;49_11;49_12;49_13;49_14;49_15;49_16;49_17;49_18;49_19;49_20;49_21;49_22;49_23;49_24;49_25;49_26;49_27;49_28;49_29;49_30;49_31;49_32;49_33;49_34;49_35;49_36;49_37;49_38;49_39;49_40;49_41;49_42;49_43;49_44;49_45;49_46;49_47;49_48;49_49;49_50;49_51;49_52;49_53;49_54;49_55;49_56;49_57;49_58;49_59;49_60;49_61;49_62;49_63;49_64;49_65;49_66;49_67;49_68;49_69;49_70;49_71;49_72;49_73;49_74;49_75;49_76;49_77;49_78;49_79;49_80;49_81;49_82;49_83;49_84;49_85;49_86;49_87;49_88;49_89;49_90;49_91;49_92;49_93;49_94;49_95;49_96;49_97;49_98;49_99;49_100;49_101;49_102;49_103;49_104;49_105;49_106;49_107;49_108;49_109;49_110;49_111;49_112;49_113;49_114;49_115;49_116;49_117;49_118;49_119;49_120;49_121;49_122;49_123;49_124;49_125;49_126;49_127;49_128;49_129;49_130;49_131;49_132;49_133;49_134;49_135;49_136;49_137;49_138;49_139;49_140;49_141;49_142;49_143;49_144;49_145;49_146;49_147;49_148;49_149;49_150;49_151;49_152;49_153;49_154;49_155;49_156;49_157;49_158;49_159;49_160;49_161;49_162;49_163;49_164; 49_165; 49_166; 49_167; 49_168; 49_169; 49_170; 49_171; 49_172; 49_173; 49_174; 49_175; 49_176; 49_177; 49_178; 49_179; 49_180; 49_181; 49_182; 49_183; 49_184; 49_185; 49_186; 49_187; 49_188; 49_189; 49_190; 49_191; 49_192; 50_1; 51_1; 52_1; 53_1; 54_1; 55_1; 56_1; 57_1; 58_1; 59_1; 60_1; 61_1; 62_1; 63_1; 64_1 and 65_1.;

[0384] For certain embodiments of the present invention, the oligonucleotide is selected from the group of oligonucleotide compounds having the following CMP ID NOs: CMP ID NO: 9_102; 9_103; 9_104; 11_1; 49_38; 49_51; 49_179; 49_189; 53_1; 56_1 and 62_1.

[0385] For certain embodiments of the present invention, the oligonucleotide is selected from the group of oligonucleotide compounds having the following CMP ID NOs: CMP ID NO: 9_102; 9_103; 9_104 and 11_1.

[0386] For certain embodiments of the present invention, the oligonucleotide is selected from the group of oligonucleotide compounds having the following CMP ID NOs: CMP ID NO: 49_38; 49_51; 49_179 and 49_189.

[0387] For certain embodiments of the present invention, the oligonucleotide is selected from the group of oligonucleotide compounds having the following CMP ID NOs: CMP ID NO: 53_1; 56_1 and 62_1.

[0388] According to the present invention, a particularly advantageous antisense oligonucleotide is an oligonucleotide compound selected from the group consisting of:

[0389]

[0390]

[0391] wherein the capital letters are β-D-oxy-LNA nucleosides, the lower case letters are DNA nucleosides, all LNA Cs are 5-methylcytosines, and all internucleoside bonds are phosphorothioate internucleoside bonds.

[0392] In one embodiment, the antisense oligonucleotide is as Figure 2 CMP ID NO: 9_103 as shown in

[0393] In one embodiment, the antisense oligonucleotide is as Figure 3 CMP ID NO: 9_104 as shown in

[0394] In one embodiment, the antisense oligonucleotide is as Figure 4 CMP ID NO: 11_1 as shown in

[0395] In one embodiment, the antisense oligonucleotide is as Figure 5 CMP ID NO: 49_38 as shown in

[0396] In one embodiment, the antisense oligonucleotide is as Figure 6 CMP ID NO: 49_189 as shown in

[0397] Manufacturing method

[0398] In yet another aspect, the present invention provides a method for manufacturing the oligonucleotides of the present invention, the method comprising reacting nucleotide units, thereby forming covalent linkages between consecutive nucleotide units in the oligonucleotide. Preferably, the method utilizes phosphoramidite chemistry (see, for example, Caruthers et al., 1987, Methods in Enzymology vol. 154, pages 287-313). In yet another embodiment, the method further comprises reacting the consecutive nucleotide sequence with a conjugating moiety (ligand) to covalently attach the conjugate moiety to the oligonucleotide. In yet another aspect, a method for manufacturing the compositions of the present invention is provided, the method comprising mixing the oligonucleotides or conjugated oligonucleotides of the present invention with a pharmaceutically acceptable diluent, solvent, carrier, salt, and / or adjuvant.

[0399] Pharmaceutically acceptable salts

[0400] Compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to conventional acid addition salts or base addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid addition salts include, for example, those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid, and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Base addition salts include those derived from ammonium, potassium, sodium, and quaternary ammonium hydroxides such as tetramethylammonium hydroxide. The chemical modification of a pharmaceutical compound into a salt is a technique well-known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability, and solubility of the compound. For example, as described in Bastin, Organic Process Research & Development 2000, 4, 427-435 or Ansel, In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457. For example, the pharmaceutically acceptable salt of the compound provided herein may be a sodium salt.

[0401] In yet another aspect, the present invention provides a pharmaceutically acceptable salt of the above antisense oligonucleotide or its conjugate. In a preferred embodiment, the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

[0402] Pharmaceutical composition

[0403] In yet another aspect, the pharmaceutical composition provided by the present invention comprises any of the above oligonucleotides and / or oligonucleotide conjugates or their salts, and a pharmaceutically acceptable diluent, carrier, salt, and / or adjuvant. Pharmaceutically acceptable diluents include phosphate buffered saline (PBS), and pharmaceutically acceptable salts include, but are not limited to, sodium salts and potassium salts. In certain embodiments, the pharmaceutically acceptable diluent is sterile phosphate buffered saline. In certain embodiments, the concentration of the oligonucleotide in the pharmaceutically acceptable diluent is a 50 to 300 micromolar solution.

[0404] Preparations suitable for use in the present invention can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief description of drug delivery methods, see, for example, Langer (Science 249: 1527-1533, 1990). WO 2007 / 031091 further provides suitable and preferred examples of pharmaceutically acceptable diluents, carriers, and adjuvants (incorporated herein by reference). WO 2007 / 031091 also discusses aspects such as appropriate dosages, formulations, routes of administration, compositions, dosage forms, combinations with other therapeutic agents, prodrug formulations, and the like.

[0405] The oligonucleotides or oligonucleotide conjugates of the present invention can be mixed with pharmaceutically acceptable active or inert substances to prepare pharmaceutical compositions or formulations. The compositions and methods for forming pharmaceutical composition formulations depend on several criteria, including but not limited to, the route of administration, the degree of the disease, or the dose to be administered.

[0406] These compositions can be sterilized by conventional disinfection techniques or filter sterilized. The aqueous solutions thus prepared can be packaged for direct use or lyophilized, and before use, the lyophilized formulation is combined with a sterile aqueous carrier for administration. The pH of the formulation is generally between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5. The solid compositions prepared can be packaged in single-dose packages, each containing a fixed amount of the above-mentioned active agent, such as a sealed package of tablets or capsules. The solid compositions can also be placed in containers to facilitate flexible adjustment of the dosage, such as in an extrusion tube for topical application of creams or ointments.

[0407] In certain embodiments, the oligonucleotides or oligonucleotide conjugates of the present invention are prodrugs. Particularly in the case of oligonucleotide conjugates, after the prodrug is delivered to the site of action such as target cells, the conjugate moiety is cleaved from the oligonucleotide.

[0408] Applications

[0409] The oligonucleotides of the present invention can be used as research reagents in fields such as diagnostics, therapeutics, and prophylaxis.

[0410] In a study, such oligonucleotides can be used to specifically regulate the synthesis of Tau protein in cells (such as in vitro cell culture) and experimental animals, thereby facilitating the functional analysis of the target, or evaluating its utility as a target for therapeutic intervention. Generally, the method of target regulation is to prevent protein formation by downregulating or inhibiting the mRNA that can produce this protein, or by downregulating or inhibiting the regulators that cause the gene or mRNA to produce this protein.

[0411] If the oligonucleotides of the present invention are used in research or diagnosis, the target nucleic acid can be cDNA or a synthetic nucleic acid derived from DNA or RNA.

[0412] The present invention provides an in vivo or in vitro method for regulating Tau expression in a target cell expressing Tau, the method comprising administering to the cell an effective amount of the oligonucleotide of the present invention.

[0413] In certain embodiments, the target cell is a mammalian cell, particularly a human cell. The target cell can be an in vitro cell culture or a part of an in vivo cell in a mammalian tissue. In a preferred embodiment, the target cell is present in the brain or central nervous system. In specific cells of the brainstem, the cerebellum, cerebral cortex, frontal cortex, medulla / pons, midbrain, and spinal cord are relevant target regions. For the treatment of progressive supranuclear palsy (PSP), a reduction in the target in the medulla / pons and midbrain regions of the brain is beneficial. For the treatment of Alzheimer's disease, a reduction in the target in the cerebral cortex, medulla / pons, and midbrain regions of the brain is beneficial. Particularly in neurons, nerve cells, axons, and basal ganglia are relevant cell types.

[0414] In diagnostics, Northern blotting, in situ hybridization, or similar techniques can be used to detect and quantify MAPT expression in cells and tissues using oligonucleotides.

[0415] In terms of treatment, oligonucleotides can be administered to an animal or a human suspected of suffering from a disease or disorder that can be treated by regulating Tau expression.

[0416] The present invention provides methods for treating or preventing a disease, the methods comprising administering to a subject suffering from or susceptible to the disease a therapeutically or prophylactically effective amount of the oligonucleotide, oligonucleotide conjugate, or pharmaceutical composition of the present invention.

[0417] The present invention also relates to oligonucleotides, compositions, or conjugates as defined herein that can be used as medicaments.

[0418] The oligonucleotides, oligonucleotide conjugates, or pharmaceutical compositions according to the present invention are generally administered in an effective amount.

[0419] The present invention also provides the use of the oligonucleotides or oligonucleotide conjugates of the present invention as described in the manufacture of a medicament for treating the disorders described herein, or provides a method for treating the disorders mentioned herein.

[0420] The diseases or disorders mentioned herein are related to the expression of Tau. In some embodiments, the disease or condition may be related to a mutation in the Tau gene or the protein product of the gene being related to or interacting with Tau. Thus, in some embodiments, the target nucleic acid is a mutant form of the Tau sequence, and in other embodiments, the target nucleic acid is a regulator of the Tau sequence.

[0421] The method of the present invention is preferably used for treating or preventing diseases caused by abnormal levels and / or activities of Tau.

[0422] The present invention further relates to the use of the oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions as defined herein in the manufacture of a medicament for treating abnormal levels and / or activities of Tau.

[0423] In one embodiment, the present invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for treating diseases selected from: Tau deposition disorders, Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD) and FTDP-17, Pick's disease (PiD), argyrophilic grain disease (AGD), tangle-predominant senile dementia (TPSD), primary age-related Tau deposition disorders (PART), Down syndrome, Guam lytico-bodig disease, infantile Tau deposition disorders, including hemimegalencephaly (HME), tuberous sclerosis complex, focal cortical dysplasia type 2b, ganglioglioma, Hallervorden-Spatz syndrome, neurodegeneration with brain iron accumulation type 1 (NBIA1), ganglioneuroma, subacute sclerosing panencephalitis, seizure disorders (epilepsy), network dysfunction (such as depression) and movement disorders (such as Parkinson's disease).

[0424] In certain embodiments, the disease is selected from Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or FTDP-17.

[0425] Administration

[0426] The oligonucleotides or pharmaceutical compositions of the present invention can be administered parenterally (e.g., intravenous injection, subcutaneous, intramuscular, intracerebral, intraventricular, intraocular or intrathecal administration).

[0427] In certain embodiments, the administration is by intrathecal administration.

[0428] Advantageously, for example, in the treatment of neurological disorders, the oligonucleotides or pharmaceutical compositions of the present invention are administered intrathecally or intracranially, e.g., by intracerebral or intraventricular administration.

[0429] The present invention also provides the use of the oligonucleotides or conjugates thereof of the present invention, such as pharmaceutical salts or compositions, in the manufacture of a medicament, wherein the medicament is in a dosage form for subcutaneous administration.

[0430] The present invention also provides the use of the oligonucleotides of the present invention, or conjugates thereof, such as pharmaceutical salts or compositions of the present invention, in the manufacture of a medicament, wherein the medicament is in a dosage form for intrathecal administration.

[0431] The present invention also provides the use of the oligonucleotides or oligonucleotide conjugates of the present invention as described in the manufacture of a medicament, wherein the medicament is in a dosage form for intrathecal administration.

[0432] Combination therapy

[0433] In certain embodiments, the oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions of the present invention are used for combination therapy with another therapeutic agent. The therapeutic agent can be, for example, a standard for caring for the above diseases or disorders.

[0434] Embodiments

[0435] The following embodiments of the present invention can be used in combination with any other embodiments described herein.

[0436] 1. An antisense oligonucleotide having a length of 10 to 50 nucleotides, comprising a continuous nucleotide sequence having a length of at least 10 nucleotides, such as 10 to 30 nucleotides, which has at least 90% complementarity, such as 100% complementarity, with any of the target sequences (R_1 to R_2254) in Table 4.

[0437] 2. The oligonucleotide according to Embodiment 1, wherein the target sequence is selected from one of target regions R_223, R_738 or R_1298, corresponding to SEQ ID NO: 3, 4 or 5, respectively.

[0438] 3. The oligonucleotide according to Embodiment 1 or 2, wherein the continuous nucleotide sequence is 100% complementary to the continuous nucleotides within positions 12051 to 12111, 39562 to 39593 or 72837 to 72940 of SEQ ID NO: 1.

[0439] 4. The anti-oligonucleotide according to any one of Embodiments 1 to 3, wherein the continuous nucleotide sequence is at least 16 nucleotides and is 100% complementary to the continuous nucleotides within positions 12060 to 12078, positions 39573 to 39592, or positions 72862 to 72890 of SEQ ID NO: 1.

[0440] 5. The oligonucleotide according to any one of Embodiments 1 to 4, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NOs: 6 to 65.

[0441] 6. The oligonucleotide according to any one of Embodiments 1 to 5, wherein the oligonucleotide comprises the sequence of SEQ ID NO: 9 or 11.

[0442] 7. The oligonucleotide according to any one of Embodiments 1 to 5, wherein the oligonucleotide comprises the sequence of SEQ ID NO: 49.

[0443] 8. The oligonucleotide according to any one of Embodiments 1 to 5, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NOs: 53, 56, and 62.

[0444] 9. The oligonucleotide according to Embodiment 1, 2, 5, or 6, wherein the continuous nucleotide sequence has zero to three mismatches compared to its complementary target sequence.

[0445] 10. The oligonucleotide according to Embodiment 9, wherein the continuous nucleotide sequence has one mismatch compared to the target sequence.

[0446] 11. The oligonucleotide according to Embodiment 9, wherein the continuous nucleotide sequence has two mismatches compared to the target sequence.

[0447] 12. The oligonucleotide according to Embodiment 9, wherein the continuous nucleotide sequence is completely complementary to the target sequence.

[0448] 13. The oligonucleotide according to any one of Embodiments 1 to 12, wherein the oligonucleotide is capable of regulating the expression of Tau.

[0449] 14. The oligonucleotide according to Embodiment 13, wherein the oligonucleotide is capable of reducing the expression of Tau.

[0450] 15. The oligonucleotide according to any one of Embodiments 1 to 14, wherein the oligonucleotide is capable of hybridizing to the target sequence with a ΔG ○ lower than -10 kcal.

[0451] 16. The oligonucleotide according to any one of Embodiments 1 to 15, wherein the target sequence is located in RNA.

[0452] 17. The oligonucleotide according to embodiment 16, wherein the RNA is mRNA.

[0453] 18. The oligonucleotide according to embodiment 17, wherein the mRNA is pre-mRNA.

[0454] 19. The oligonucleotide according to embodiments 1 to 18, wherein the continuous nucleotide sequence comprises or consists of at least 14 consecutive nucleotides, particularly 15, 16, 17, 18, 19, 20, 21, or 22 consecutive nucleotides.

[0455] 20. The oligonucleotide according to embodiments 1 to 18, wherein the continuous nucleotide sequence comprises or consists of 16 to 22 nucleotides.

[0456] 21. The oligonucleotide according to embodiment 20, wherein the continuous nucleotide sequence comprises or consists of 18 to 20 nucleotides.

[0457] 22. The oligonucleotide according to embodiments 1 to 21, wherein the oligonucleotide comprises or consists of 14 to 30 nucleotides in length.

[0458] 23. The oligonucleotide according to embodiment 22, wherein the oligonucleotide comprises or consists of 16 to 24 nucleotides in length.

[0459] 24. The oligonucleotide according to embodiment 22 or 24, wherein the oligonucleotide comprises or consists of 18 to 20 nucleotides in length.

[0460] 25. The oligonucleotide according to embodiments 1 to 24, wherein the oligonucleotide or the continuous nucleotide sequence is single-stranded.

[0461] 26. The oligonucleotide according to embodiments 1 to 25, wherein the oligonucleotide is neither siRNA nor self-complementary.

[0462] 27. The oligonucleotide according to embodiments 1 to 26, which comprises one or more modified nucleosides.

[0463] 28. The oligonucleotide according to embodiment 27, wherein the one or more modified nucleosides are high-affinity modified nucleosides.

[0464] 29. The oligonucleotide according to embodiment 27 or 28, wherein the one or more modified nucleosides are 2'-sugar modified nucleosides.

[0465] 30. The oligonucleotide according to Embodiment 29, wherein the one or more 2'-sugar modified nucleosides are independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, 2'-fluoro-ANA, and LNA nucleosides.

[0466] 31. The oligonucleotide according to Embodiment 29 or 30, wherein the one or more 2'-sugar modified nucleosides are LNA nucleosides.

[0467] 32. The antisense oligonucleotide according to Embodiment 31, wherein the LNA nucleosides are selected from oxy-LNA, amino-LNA, thio-LNA, cET, and ENA.

[0468] 33. The antisense oligonucleotide according to Embodiment 31 or 32, wherein the modified LNA nucleoside is oxy-LNA having the following 2'-4' bridge -O-CH 2 -.

[0469] 34. The antisense oligonucleotide according to Embodiment 33, wherein the oxy-LNA is β-D-oxy-LNA.

[0470] 35. The antisense oligonucleotide according to Embodiment 31 or 32, wherein the modified LNA nucleoside is cET having the following 2'-4' bridge -O-CH(CH 3 )-.

[0471] 36. The antisense oligonucleotide according to Embodiment 35, wherein the cET is (S)cET, i.e., 6'(S)-methyl-β-D-oxy-LNA.

[0472] 37. The antisense oligonucleotide according to Embodiment 31 or 32, wherein the LNA is ENA, having the following 2'-4' bridge -O-CH 2 -CH 2 -.

[0473] 38. The oligonucleotide according to Embodiment 29 or 30, wherein the one or more 2'-sugar modified nucleosides are MOE nucleosides.

[0474] 39. The oligonucleotide according to any one of Embodiments 1 to 38, wherein the oligonucleotide comprises at least one modified internucleoside bond.

[0475] 40. The oligonucleotide according to Embodiment 39, wherein the modified internucleoside bond is nuclease-resistant.

[0476] 41. The oligonucleotide according to Embodiment 39 or 40, wherein at least 50% of the internucleoside bonds within the continuous nucleotide sequence are phosphorothioate internucleoside bonds or boranophosphate internucleoside bonds.

[0477] 42. An oligonucleotide according to embodiment 39 or 41, wherein 80% of the internucleoside linkages within the continuous nucleotide sequence are phosphorothioate internucleoside linkages.

[0478] 43. An oligonucleotide according to embodiments 39 to 42, wherein all of the internucleoside linkages within the continuous nucleotide sequence are phosphorothioate internucleoside linkages.

[0479] 44. An oligonucleotide according to embodiments 1 to 43, wherein the oligonucleotide is capable of recruiting ribonuclease H.

[0480] 45. An oligonucleotide according to embodiment 44, wherein the oligonucleotide or the continuous nucleotide sequence is a nicked body.

[0481] 46. An oligonucleotide according to embodiment 45, wherein the nicked body has the formula 5'-F-G-F'-3', wherein the F and F' wing regions independently comprise or consist of 1 to 8 nucleosides, wherein 2 to 5 are 2'-sugar modified nucleosides according to embodiments 0 to 0, and G is a region between 6 and 16 nucleosides capable of recruiting ribonuclease H.

[0482] 47. An antisense oligonucleotide according to embodiment 46, wherein each wing region (F and F') is characterized by having at least one 2'-sugar modified nucleoside at the 5' end, and the 3' end of the wing and the G region have a DNA nucleoside adjacent to the wing region (such as the 5' and 3' ends of the G region).

[0483] 48. An oligonucleotide according to embodiment 46 or 47, wherein all of the 2'-sugar modified nucleosides in regions F and F' are the same LNA nucleoside.

[0484] 49. An oligonucleotide according to embodiment 48, wherein all of the LNA nucleosides are oxy-LNA nucleosides.

[0485] 50. An oligonucleotide according to embodiment 46 or 47, wherein all of the 2'-sugar modified nucleosides in regions F and F' are the same MOE nucleoside.

[0486] 51. An oligonucleotide according to embodiments 46 to 50, wherein

[0487] a. The F region has a length between 3 and 8 nucleotides and consists of 3 to 5 identical LNA nucleosides and 0 to 4 DNA nucleosides; and

[0488] b. The F' region has a length between 2 and 6 nucleotides and consists of 2 to 4 identical LNA nucleosides and 0 to 2 DNA nucleosides; and

[0489] c. Region G is between 6 and 14 DNA nucleotides.

[0490] 52. An oligonucleotide according to embodiment 46 or 47, wherein at least one of regions F or F' further comprises at least one 2'-substituted modified nucleoside independently selected from the group consisting of: 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, and 2'-fluoro-DNA.

[0491] 53. An oligonucleotide according to embodiments 46 to 50 or 52, wherein the ribonuclease H-recruiting nucleosides in region G are selected from DNA, α-L-LNA, C4'-alkylated DNA, ANA, and 2'F-ANA and UNA.

[0492] 54. An oligonucleotide according to embodiment 53, wherein the nucleosides in region G are DNA and / or α-L-LNA nucleosides.

[0493] 55. An oligonucleotide according to embodiment 53 or 54, wherein region G consists of at least 75% DNA nucleosides.

[0494] 56. An oligonucleotide according to embodiments 53 to 55, wherein all nucleotides in region G are DNA.

[0495] 57. An oligonucleotide according to embodiments 1-56, wherein the oligonucleotide is selected from CMP ID NO: 9_102; 9_103; 9_104; 11_1; 49_38; 49_51; 49_179; 49_189; 53_1; 56_1, and 62_1.

[0496] 58. An oligonucleotide according to embodiment 57, wherein the oligonucleotide is selected from the following compounds:

[0497]

[0498]

[0499] wherein the capital letters are β-D-oxy-LNA nucleosides, the lowercase letters are DNA nucleosides, all LNA Cs are 5-methylcytosine, and all internucleoside bonds are phosphorothioate internucleoside bonds.

[0500] 59. An antisense oligonucleotide according to any one of embodiments 1 to 58, wherein the antisense oligonucleotide is CMP ID NO: 9_103 as shown in Figure 2 as shown in.

[0501] 60. An antisense oligonucleotide according to any one of embodiments 1 to 58, wherein the antisense oligonucleotide is as shown in Figure 3The CMP ID NO: 9_104 shown in

[0502] 61. An antisense oligonucleotide according to any one of Embodiments 1 to 58, wherein the antisense oligonucleotide is as shown in Figure 4 The CMP ID NO: 11_1 shown in

[0503] 62. An antisense oligonucleotide according to any one of Embodiments 1 to 58, wherein the antisense oligonucleotide is as shown in Figure 5 The CMP ID NO: 49_38 shown in

[0504] 63. An antisense oligonucleotide according to any one of Embodiments 1 to 58, wherein the antisense oligonucleotide is as shown in Figure 6 The CMP ID NO: 49_189 shown in

[0505] 64. A conjugate comprising an oligonucleotide according to any one of Claims 1 to 58, and at least one conjugate moiety covalently attached to the oligonucleotide.

[0506] 65. The oligonucleotide conjugate according to Embodiment 59, wherein the conjugate moiety is selected from carbohydrates, cell surface receptor ligands, active ingredients, hormones, lipophilic substances, polymers, proteins, peptides, toxins, vitamins, viral proteins, or combinations thereof.

[0507] 66. The oligonucleotide conjugate according to Embodiment 59 or 65, wherein the conjugate facilitates delivery across the blood-brain barrier.

[0508] 67. The oligonucleotide conjugate according to Embodiment 66, wherein the conjugate is an antibody or antibody fragment targeting the transferrin receptor.

[0509] 68. The oligonucleotide conjugate according to Embodiments 59 to 67, comprising a linker located between the oligonucleotide and the conjugate.

[0510] 69. The oligonucleotide conjugate according to Embodiment 68, wherein the linker is a physiologically labile linker.

[0511] 70. A pharmaceutical composition comprising the oligonucleotide of Embodiments 1 to 58 or the conjugate of Embodiments 59 to 69, and a pharmaceutically acceptable diluent, carrier, salt, and / or adjuvant.

[0512] 71. A method for manufacturing the oligonucleotide of Embodiments 1 to 58, comprising reacting nucleotide units to thereby form a continuous nucleotide unit with a covalent linkage contained in the oligonucleotide.

[0513] 72. The method of embodiment 71, further comprising reacting the continuous nucleotide sequence with a non-nucleotide conjugate moiety.

[0514] 73. A method for manufacturing the composition of embodiment 70, comprising mixing the oligonucleotide with a pharmaceutically acceptable diluent, carrier, salt, and / or adjuvant.

[0515] 74. An in vivo or in vitro method for modulating Tau expression in a target cell expressing Tau, the method comprising administering to the cell an effective amount of an oligonucleotide of embodiments 1 to 57, or a conjugate of embodiments 59 to 69, or a pharmaceutical composition of embodiment 70.

[0516] 75. A method for treating or preventing a disease, comprising administering to a subject suffering from or susceptible to the disease a therapeutically or prophylactically effective amount of an oligonucleotide of embodiments 1 to 58, or a conjugate of embodiments 59 to 69, or a pharmaceutical composition of embodiment 70.

[0517] 76. An oligonucleotide of embodiments 1 to 57, or a conjugate of embodiments 59 to 69, or a pharmaceutical composition of embodiment 70, which is used as a drug for treating or preventing a disease in an individual.

[0518] 77. Use of an oligonucleotide of embodiments 1 to 58, or a conjugate of embodiments 59 to 69, for preparing a drug for treating or preventing a disease in an individual.

[0519] 78. The method, oligonucleotide, or use of embodiments 75 to 77, wherein the disease is related to the in vivo activity of Tau.

[0520] 79. The method, oligonucleotide, or use of embodiments 75 to 78, wherein the disease is related to the overexpression and / or abnormal level of Tau.

[0521] 80. The method, oligonucleotide, or use of embodiment 79, wherein, compared to the expression without the oligonucleotide of embodiments 1 to 58, or the conjugate of embodiments 59 to 69, or the pharmaceutical composition of embodiment 70, the Tau is reduced by at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%.

[0522] 81. The method, oligonucleotide or use as described in Embodiments 75 to 79, wherein the disease is selected from Tau abnormal deposition lesions, Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD) and FTDP-17, Pick's disease (PiD), argyrophilic grain disease (AGD), tangle-predominant senile dementia (TPSD), primary age-related Tau abnormal deposition lesions (PART), Down syndrome, Guam lytico-bodig disease, infantile Tau abnormal deposition lesions, including hemimegalencephaly (HME), tuberous sclerosis complex, focal cortical dysplasia type 2b, ganglioglioma, Hallervorden-Spatz syndrome, neurodegeneration with brain iron accumulation type 1 (NBIA1), gangliocytoma, subacute sclerosing panencephalitis, seizure disorders (epilepsy), network dysfunction (such as depression) and movement disorders (such as Parkinson's disease).

[0523] 82. The method, oligonucleotide or use as described in Embodiments 75 to 79, wherein the disease is selected from Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or FTDP-17.

[0524] 83. The method, oligonucleotide or use as described in Embodiments 75 to 82, wherein the subject is a mammal.

[0525] 84. The method, oligonucleotide or use as described in Embodiment 83, wherein the mammal is a human.

[0526] The present invention also includes the following items:

[0527] 1. An antisense oligonucleotide having a length of 10 to 30 nucleotides, the antisense oligonucleotide comprising a continuous nucleotide sequence having a length of at least 10 nucleotides, the continuous nucleotide sequence having at least 90% complementarity with the continuous nucleotides within positions 12051 to 12111, 39562 to 39593 or 72837 to 72940 of SEQ ID NO: 1.

[0528] 2. The antisense oligonucleotide as described in Item 1, wherein the continuous nucleotide sequence is at least 16 nucleotides and is 100% complementary to the continuous nucleotides within positions 12060 to 12078, 39573 to 39592 or positions 72862 to 72890 of SEQ ID NO: 1.

[0529] 3. The antisense oligonucleotide as described in item 1 or 2, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 9, 11, 49, 53, 56, and 62.

[0530] 4. The antisense oligonucleotide as described in any one of items 1 to 3, wherein the oligonucleotide is capable of reducing the expression of Tau.

[0531] 5. The antisense oligonucleotide as described in any one of items 1 to 4, wherein the continuous nucleotide sequence comprises one or more nucleosides modified at the 2'-sugar.

[0532] 6. The antisense oligonucleotide as described in item 5, wherein the one or more nucleosides modified at the 2'-sugar are independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabinonucleic acid (ANA), 2'-fluoro-ANA, and LNA nucleosides.

[0533] 7. The antisense oligonucleotide as described in item 5 or 6, wherein the continuous nucleotide sequence comprises 4 to 8 LNA nucleosides.

[0534] 8. The antisense oligonucleotide as described in any one of items 1 to 7, wherein at least 80% of the internucleoside linkages within the continuous nucleotide sequence are phosphorothioate internucleoside linkages.

[0535] 9. The antisense oligonucleotide as described in any one of items 1 to 8, wherein the oligonucleotide is capable of recruiting ribonuclease H.

[0536] 10. The antisense oligonucleotide as described in item 9, wherein the antisense oligonucleotide or its continuous nucleotide sequence consists of a gapmer of the formula 5'-F-G-F'-3' or comprises a gapmer of the formula 5'-F-G-F'-3', wherein the F and F' regions independently comprise 1 to 8 nucleosides, wherein 2 to 5 are modified at the 2'-sugar and define the 5' and 3' ends of the F and F' regions, and G is a region between 6 and 16 nucleosides capable of recruiting ribonuclease H, such as a region comprising 6 to 16 DNA nucleosides.

[0537] 11. The antisense oligonucleotide as described in any one of items 1 to 10, wherein the antisense oligonucleotide is a compound selected from the group consisting of:

[0538] CTTtAATttaatcactcAT SEQ ID NO: 9; CMP ID NO: 9_102

[0539] CTTTaatttaatcacTCAT SEQ ID NO: 9; CMP ID NO: 9_103

[0540] CTTTaatttaatcaCtCAT SEQ ID NO: 9; CMP ID NO: 9_104

[0541] CTTTaatttaatcaCTCA SEQ ID NO: 11; CMP ID NO: 11_1

[0542] TtaaCTCAaatcaaTtctCA SEQ ID NO: 49; CMP ID NO: 49_38

[0543] TtaActCAaatcaattCTCA SEQ ID NO: 49; CMP ID NO: 49_51

[0544] TTAactCaaatcaatTCtCASEQ ID NO: 49; CMP ID NO: 49_179

[0545] TTAActcaaatcaattCTCASEQ ID NO: 49; CMP ID NO: 49_189

[0546] CAACaccttttaattcATTA SEQ ID NO: 53; CMP ID NO: 53_1

[0547] CTCAtcaacaccttttaaTT SEQ ID NO: 56; CMP ID NO: 56_1

[0548] TTAactcatcaacaCCTT SEQ ID NO: 62; CMP ID NO: 62_1

[0549] Among them, the capital letters are β-D-oxy LNA nucleotides, the lowercase letters are DNA nucleotides, all LNA Cs are 5-methylcytosines, and all internucleoside linkages are phosphorothioate internucleoside linkages.

[0550] 12. The antisense oligonucleotide according to any one of Items 1 to 11, wherein the antisense oligonucleotide is the CMP ID NO: 9_103 as shown in Figure 2 as follows.

[0551] 13. The antisense oligonucleotide according to any one of Items 1 to 11, wherein the antisense oligonucleotide is the CMP ID NO: 9_104 as shown in Figure 3 as follows.

[0552] 14. The antisense oligonucleotide according to any one of Items 1 to 11, wherein the antisense oligonucleotide is CMP ID NO: 11_1 as shown in Figure 4 the figure.

[0553] 15. The antisense oligonucleotide according to any one of Items 1 to 11, wherein the antisense oligonucleotide is CMP ID NO: 49_38 as shown in Figure 5 the figure.

[0554] 16. The antisense oligonucleotide according to any one of Items 1 to 11, wherein the antisense oligonucleotide is CMP ID NO: 49_189 as shown in Figure 6 the figure.

[0555] 17. A conjugate comprising the antisense oligonucleotide according to any one of Items 1 to 16, and at least one conjugate moiety covalently attached to the oligonucleotide.

[0556] 18. A pharmaceutically acceptable salt of the antisense oligonucleotide according to any one of Items 1 to 16 or the conjugate according to Item 17.

[0557] 19. A pharmaceutical composition comprising the antisense oligonucleotide according to any one of Items 1 to 16 or the conjugate according to Item 17, and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

[0558] 20. An in vivo or in vitro method for regulating Tau expression in target cells expressing Tau, the method comprising administering to the cells an effective amount of the antisense oligonucleotide according to any one of Items 1 to 16 or the conjugate according to Item 17 or the pharmaceutical composition according to Item 19.

[0559] 21. A method for treating or preventing a disease, the method comprising administering to a subject suffering from or susceptible to the disease a therapeutically or prophylactically effective amount of the antisense oligonucleotide according to any one of Items 1 to 16 or the conjugate according to Item 17 or the pharmaceutical composition according to Item 19.

[0560] 22. The method according to Item 21, wherein the disease is selected from the group consisting of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), or FTDP-17.

[0561] 23. The method according to Item 22, wherein the disease is progressive supranuclear palsy (PSP).

[0562] 24. The antisense oligonucleotide as described in any one of Items 1 to 16, or the conjugate as described in Item 17, or the pharmaceutical composition as described in Item 19, which is used for pharmaceuticals.

[0563] 25. The antisense oligonucleotide as described in any one of Items 1 to 16, or the conjugate as described in Item 17, or the pharmaceutical composition as described in Item 19, which is used for the treatment or prevention of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), or FTDP-17.

[0564] 26. The antisense oligonucleotide, conjugate, or pharmaceutical composition for treatment as described in Item 25, wherein the disease is progressive supranuclear palsy (PSP).

[0565] 27. Use of the antisense oligonucleotide as described in Items 1 to 16, or the conjugate as described in Item 17, or the pharmaceutical composition as described in Item 19 in the preparation of a medicament for the treatment or prevention of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), or FTDP-17.

[0566] Examples

[0567] Materials and Methods

[0568] Oligonucleotide Motif Sequences and Oligonucleotide Compounds

[0569] Table 5: List of oligonucleotide motif sequences (represented by SEQ ID NO), their designs, and specific oligonucleotide compounds designed based on the motif sequences (represented by CMP ID NO).

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589] The motif sequence represents a continuous sequence of nucleobases present in an oligonucleotide.

[0590] The design refers to the nicked body design, F-G-F'. In a classical nicked body design, such as 3-10-3, all nucleotides in the flanks (F and F′) are composed of the same 2′-sugar modified nucleosides, such as LNA, cET, or MOE, and a stretch of DNA forms a nick (G) in the middle. In a nicked body with an alternating flank design, the flanks of the oligonucleotide are annotated as a series of integers representing a number of 2’-sugar modified nucleosides (M), followed by a number of DNA nucleosides (D). For example, a flank with a 2-2-1 motif represents 5’[M]2-[D]2-[M]3’ and a 1-1-1-1-1 motif represents 5’[M]-[D]-[M]-[D]-[M]3’. Both flanks have 2’-sugar modified nucleosides at the 5’ and 3’ ends. A nick region (G) composed of a number of DNA nucleosides (usually between 6 and 16) is located between the flanks.

[0591] The title "Oligonucleotide Compound" in the table represents a specific design of the motif sequence. Capital letters represent β-D-oxy-LNA nucleosides, underlined capital letters represent MOE nucleosides, lowercase letters represent DNA nucleosides, all LNA Cs are 5-methylcytosines, e represents 5-methylcytosine DNA, all internucleoside bonds are phosphorothioate internucleoside bonds (unless marked with subscript letters between nucleotides), and subscript o represents a phosphodiester bond.

[0592] Oligonucleotide synthesis

[0593] Oligonucleotide synthesis is well known in the art. The following describes the synthesis methods that can be used. The manufacturing method of the oligonucleotides of the present invention may vary slightly in terms of the equipment used, the support, and the concentration.

[0594] On Oligomaker 48, oligonucleotides were synthesized on a uridine universal support by the phosphoramidite method at 1 micromole scale. At the end of the synthesis, the oligonucleotides were cleaved from the support by treatment with ammonia water at 60 °C for 5 to 16 hours. The purification of the oligonucleotides was carried out using reverse-phase HPLC (RP-HPLC) or solid-phase extraction, followed by characterization using UPLC and further determination of the molecular mass using ESI-MS.

[0595] Extension of oligonucleotides:

[0596] Using a 0.1 molar solution of 5'-O-DMT-protected amide in acetonitrile and an acetonitrile (0.25 molar) solution of DCI (4,5-dicyanoimidazole) as activators, coupling of β-cyanoethyl-phosphoramidites (DNA-A(Bz), DNA-G(ibu), DNA-C(Bz), DNA-T, LNA-5-methyl-C(Bz), LNA-A(Bz), LNA-G(dmf) or LNA-T) was carried out. In the final cycle, phosphoramidites with the desired modifications, such as a C6 linker for attaching a conjugate group or the conjugate group itself, could be used. To introduce phosphorothioate bonds, thiolation was performed using xanthogenic acid (0.01 molar in acetonitrile / pyridine 9:1). Phosphodiester bonds could be introduced using 0.02 molar iodine in THF / pyridine / water 7:2:1. The remaining reagents were those commonly used in oligonucleotide synthesis.

[0597] Post-solid-phase synthesis conjugation could be carried out using commercially available C6 amino linker phosphoramidite in the final cycle of solid-phase synthesis. After deprotection and cleavage from the support, the amino-linked deprotected oligonucleotides could be isolated. Then, using standard synthesis methods, conjugates were introduced through activation of functional groups.

[0598] Purification by RP-HPLC:

[0599] The crude product compounds were purified using preparative RP-HPLC on a Phenomenex Jupiter C18 10μ 150x10 mm column. Ammonium acetate at 0.1 molar with a pH of 8 and acetonitrile were used as buffers, and the flow rate was 5 ml per minute. The collected fractions were lyophilized to yield the purified compounds, which were usually in the form of white solids.

[0600] Abbreviations:

[0601] DCI: 4,5-dicyanoimidazole

[0602] DCM: Dichloromethane

[0603] DMF: Dimethylformamide

[0604] DMT: 4,4'-dimethoxytrityl

[0605] THF: tetrahydrofuran

[0606] Bz: benzoyl

[0607] Ibu: isobutyryl

[0608] RP-HPLC: reverse phase high performance liquid chromatography

[0609] T m Assay:

[0610] Dilute the oligonucleotide and RNA target (phosphate-linked, PO) duplex to 3 mM in 500 ml of ribonuclease-free water, and then mix with 500 ml of 2x T m buffer (200 mM sodium chloride, 0.2 mM EDTA, 20 mM sodium phosphate, pH 7.0). Heat the solution to 95 °C and maintain for 3 minutes, then allow to anneal at room temperature for 30 minutes. Measure the duplex melting temperature (T m ) on a Lambda 40 UV / VIS spectrophotometer equipped with a Peltier temperature programmer PTP6 using PE Templab software (Perkin Elmer). The temperature is ramped from 20 °C to 95 °C and then cooled to 25 °C, and the absorbance is recorded at 260 nm. Evaluate the duplex T m .

[0611] Primary neuron cell culture

[0612] Primary neuronal cultures were established from the forebrains of E18 transgenic mice expressing a human tau transgene on a murine tau knockout background. (Andorfer et al., J Neurochem 86:582-590 (2003)). Primary neurons were generated by papain digestion according to the manufacturer's protocol (Worthington Biochemical Corporation, LK0031050). Briefly, the forebrains were dissected from hTau mice E18 BAC-Tg embryos expressing the full-length human microtubule-associated protein Tau (MAPT) gene on a murine MAPT null background and incubated in papain / DNase (deoxyribonuclease) / Earle's balanced salt solution (EBSS) solution at 37°C for 30 to 45 minutes. After trituration and centrifugation of the cell pellet, the reaction was terminated by incubation with EBSS containing protease inhibitors, bovine serum albumin (BSA), and deoxyribonuclease. The cells were triturated and washed with Neurobasal (NB, Invitrogen) supplemented with 2% B-27, 100 μg / ml penicillin, 85 μg / ml streptomycin, and 0.5 mM glutamine.

[0613] Transgenic Tau mice (hTau mice)

[0614] Male and female transgenic mice (30-40 g) expressing a tau transgene, which was derived from a human PAC (H1 haplotype driven by the tau promoter) (Polydor et al., J. Neurosci. (2009) 29(34):10741-9), and in which the native murine Tau gene line had been deleted, were used to evaluate tolerability, pharmacodynamic endpoints, and tissue drug concentrations.

[0615] Animals were housed in a colony room maintained at a constant temperature (21 ± 2°C) and humidity (50 ± 10%) and were exposed to light for 12 hours per day (lights on at 6:00 am). All animals had free access to food and water during the study period. Behavioral studies were conducted between 0700 and 1500 hours.

[0616] Intracerebroventricular (ICV) injections were performed using a Hamilton microsyringe equipped with a 27- or 30-gauge needle according to the method of Haley and McCormick. The needle was equipped with a polyethylene shield 2.5 mm from the tip to limit its penetration into the brain. Mice were anesthetized with isoflurane anesthetic (1.5-4%). The mice to be injected were grasped by the loose skin behind the neck with the thumb and index finger of one hand. Gentle but steady pressure was applied, and then the animal's head was fixed by pressing against a firm flat surface. The needle tip was then inserted through the scalp and skull, approximately 1 mm lateral and 1 mm caudal to the bregma. Once the needle was positioned, the ASO was administered in a volume of 5 μL in saline vehicle and injected into the right (or left) lateral ventricle over 20 to 30 seconds. The needle was left in place for 10 seconds before removal. This procedure did not require surgery or incision. The animals were placed on a heating pad to keep warm until they recovered from the procedure.

[0617] Three days and / or 4 weeks after administration, the mice were sacrificed with an overdose of isoflurane and then quickly decapitated, and the brain tissue (right, frontal cortex region) was collected on dry ice for later Tau qPCR.

[0618] Medium for culturing and differentiating human stem cell-derived neurons

[0619] N2B27 + SFA medium = N2B27 + S, F, A cytokines

[0620]

[0621]

[0622] N2B27 + BGAA medium = N2B27 + B, G, Aa, cA cytokines + P / S + laminin

[0623]

[0624] Example 1 In vitro screening of ASO targeting the MAPT intron

[0625] Antisense oligonucleotide (ASO) screening was performed in primary neuronal cells from humanized Tau mice (807 ASO targeting the MAPT intron).

[0626] By Analyze and measure the ability of ASO to reduce MAPT mRNA in vitro. Each reduction in tau mRNA was normalized by subtracting the assay background signal and normalizing each well to the housekeeping gene tubulin mRNA signal.

[0627] Primary neuronal cell cultures were prepared as described in the "Materials and Methods" section and plated at 10,000 cells per well on poly-D-lysine-coated 384-well plates and maintained in Neurobasal medium supplemented with B27, glutamax, and penicillin-streptomycin. The ASO was diluted in water and added to the DIV01 cells to a final concentration of 0.5 μM. After addition of the ASO, the neurons were incubated at 37 °C and 5% CO 2 2 for 5 days to achieve a steady-state reduction in mRNA. The medium was removed and the cells were washed once in DPBS. Measurement of lysate messenger RNA was performed using 2.0 Reagent System which uses branched DNA signal amplification to quantify RNA and relies on a specifically designed set of RNA capture probes. The cell lines were lysed using a working cell lysis buffer prepared by adding 50 μl of proteinase K to 5 ml of pre-warmed lysis mix and diluted to a 1:4 final dilution with dH 2 2O. The working lysis buffer was added to the plates (45 μl / well), mixed by grinding, sealed, and incubated at 55 °C for 30 minutes. After lysis, the wells were stored at -80 °C or assayed immediately.

[0628] Depending on the specific capture probe used (tau or tubulin), the lysate was diluted in the lysis mix. Then a total volume of 27 μl / well was added to the capture plate (a 384-well polystyrene plate coated with the capture probe). According to the manufacturer's instructions ( 2.0 ) The working probe set reagent is generated by combining 2.2 ml of nuclease-free water, 1.2 ml of lysis mixture, 184 μl of blocking reagent, and 66.8 μl of specific 2.0 probe set (human MAPT, catalog #15486) and mouse β3-tubulin (catalog #SB-17245). Then, 7 μl of the working probe set reagent is added to 27 μl of the lysate dilution (or 27 μl of the lysis mixture for background samples) on the capture plate. The plate is centrifuged and then incubated at 55 °C for 16 - 20 hours for hybridization (target RNA capture). Signal amplification and detection of the target RNA are initiated by washing the plate 3 times with buffer to remove unbound materials. 2.0 Pre-Amplifier hybridization reagent (30 μl / well) is added, incubated at 55 °C for 1 hour, then aspirated and washing buffer is added and aspirated 3 times. Then, 2.0 Amplifier hybridization reagent (30 μl / well) is added as described, incubated at 55 °C for 1 hour and the washing is repeated as before. Next, 2.0 Label Probe hybridization reagent (30 μl / well) is added, incubated at 50 °C for 1 hour and the washing is repeated as before. Finally, the plate is centrifuged to remove any excess washing buffer and 2.0 substrate (30 μl / well) is added. The plate is incubated at room temperature for 5 minutes and imaged on a PerkinElmer Envision multimode plate reader in luminescence mode within 15 minutes.

[0629] For the gene of interest, the average assay background signal is subtracted from the average signal of each technical replicate. The average background-subtracted signal of the gene of interest is divided by the average background-subtracted signal of the housekeeping tubulin RNA. The percent inhibition of the treated sample is calculated relative to the untreated sample (i.e., the lower the value, the greater the inhibition). Background variability in the untreated sample can result in the percent inhibition of the treated sample being equal to or higher than the background, and in these cases, the percent inhibition is expressed as 100% control inhibition (i.e., no inhibition).

[0630] Figure 1 Shows the MAPT mRNA reduction achieved by all 807 ASOs. In the figure, three regions A, B, and C on the MAPT target nucleic acid are shown. The ASOs in these regions have a high prevalence, and the target is reduced to 40% or lower compared to the control group (100%).

[0631] Example 2 In Vitro Screening of ASOs Targeting Selected Regions on MAPT

[0632] Based on the screening in Example 1, a new ASO library was designed to target regions A, B, and C, as Figure 1 shown. The motif sequences and oligonucleotide compounds are shown in Table 5 above.

[0633] Screen as described in Example 1. The results are shown in Table 6.

[0634] Table 6 In vitro screening of anti-MAPT compounds

[0635]

[0636]

[0637]

[0638]

[0639]

[0640]

[0641]

[0642]

[0643]

[0644]

[0645]

[0646]

[0647]

[0648]

[0649]

[0650]

[0651]

[0652]

[0653]

[0654]

[0655]

[0656]

[0657]

[0658]

[0659]

[0660]

[0661]

[0662]

[0663]

[0664]

[0665]

[0666]

[0667]

[0668] IC50 value of the oligonucleotides selected in Example 3

[0669] Using a 96-well assay, the IC50 of some of the best-performing oligonucleotides from Example 2 was determined in primary neuronal cells in vitro.

[0670] The primary neuronal cell culture line was prepared as described in the "Materials and Methods" section and plated at 50,000 cells per well on poly-D-lysine-coated 96-well plates and maintained in Neurobasal medium containing B27, glutamax, and penicillin-streptomycin. The ASO was diluted in water (for IC50 determination) and added to the cells 1 day after plating (DIV01). For IC 50 determination, the neurons were treated at the highest concentration of 0.5 to 5 μM, and an approximately 1:4 dilution factor of concentration responses was used to define the IC50. The CMP ID NO: 66_1 corresponding to ASO-001933 in WO2016 / 126995 was used as a positive control. After ASO treatment, the neurons were incubated at 37 °C for 5 days to achieve a steady-state reduction of mRNA. The medium was removed and the cells were lysed as follows. Measurement of lysate messenger RNA was performed using 2.0 Reagent System which uses branched DNA signal amplification method to quantify RNA relying on a specific set of RNA capture probes. The working cell lysis buffer was made by adding 50 μl of proteinase K to 5 ml of pre-warmed lysis mixture and made up to volume with dH 2Dilute to a final dilution of 1:4. Add the working lysis buffer to the plate (150 μl / well), grind and mix, seal, and incubate at 55 °C for 30 minutes. After lysis, store the wells at -80 °C or assay immediately.

[0671] Depending on the specific capture probe used (tau or tubulin), dilute the lysate in the lysis mixture. Then add a total of 80 μl / well to the capture plate (96-well polystyrene plate coated with the capture probe). According to the manufacturer's instructions The working probe set reagent is generated by combining 12.1 μl of nuclease-free water, 6.6 μl of the lysis mixture, 1 μl of the blocking reagent, 0.3 μl of the specific 2.0 probe set (human MAPT, catalog #15486) and either mouse β3-tubulin (catalog #SB-17245). Then add 20 μl of the working probe set reagent to the 80 μl of lysate dilution (or 80 μl of lysis mixture for background samples) on the capture plate. Centrifuge the plate and then incubate at 55 °C for 16 - 20 hours for hybridization (target RNA capture). Start signal amplification and detection of the target RNA by washing the plate 3 times with buffer to remove unbound material. Add the 2.0 Pre-Amplifier hybridization reagent (100 μl / well), incubate at 55 °C for 1 hour, then aspirate and add the wash buffer and aspirate 3 times. Then add the 2.0 Amplifier hybridization reagent (100 μl / well) as described, incubate at 55 °C for 1 hour and repeat the washing as before. Next, add the 2.O Label Probe hybridization reagent (100 μl / well), incubate at 50 °C for 1 hour and repeat the washing as before. Finally, centrifuge the plate to remove any excess wash buffer and add the 2.0 substrate (100 μl / well). Incubate the plate at room temperature for 5 minutes and image the plate on a PerkinElmer Envision multimode plate reader in luminescence mode within 15 minutes.

[0672] Data determination: For the gene of interest, subtract the average assay background signal from the average signal of each technical replicate. Divide the average background-subtracted signal of the gene of interest by the average background-subtracted signal of the housekeeping tubulin RNA. The percent inhibition of the treated sample is calculated relative to the untreated sample (i.e., the lower the value, the greater the inhibition). Background variability in the untreated sample can result in the percent inhibition of the treated sample being equal to or higher than the background, and in these cases, the percent inhibition is expressed as 100% control inhibition (i.e., no inhibition). The results are shown in Table 7.

[0673] Table 7: IC50 of anti-MAPT compounds

[0674] CMP ID NO Compound Region IC50 (nM) 9_103 CTTTaatttaatcacTCAT A 12.2 11_1 CTITaatttaatcaCTCA A 9.4 34_1 GAATattacaccATCC A 32.0 37_1 CAGAatattacaCCAT A 15.6 49_189 TTAActcaaatcaattCTCA B 11.8 56_1 CTCAtcaacaccttttaaTT C 44.0 62_1 TTAactcatcaacaCCTT C 40.5 63_1 TTAActcatcaacACCT C 37.1 66_1 AtTTCcaaattcactTTtAC - 44.3

[0675] Example 4 In Vivo Tolerance and In Vivo Tau mRNA Reduction

[0676] Some of the top-performing oligonucleotides from Example 2 were assayed in humanized Tau mice in vivo to evaluate acute tolerance and MAPT mRNA reduction in the CNS at 3 or 28 days after a single injection.

[0677] Transgenic Tau mice were administered 100 μg of ASO by intracerebroventricular (ICV) injection (see Materials and Methods section, transgenic Tau mice). CMP ID NO: 66_1 corresponding to ASO-001933 in WO2016 / 126995 was used as a positive control. Animals were observed for behavioral side effects for one hour after a single ICV injection of ASO. The acute tolerance score for the severity of side effects ranged from zero (no side effects) to 20 (spasms leading to euthanasia). The tolerance scale was divided into 5 neurobehavioral categories: 1) hyperactivity 2) reduced activity and arousal 3) motor dysfunction / ataxia 4) abnormal posture and respiration and 5) tremors / twitching. Each category was scored on a scale of 0 - 4, with the worst possible total score of 20. Animals were observed for behavioral changes in their home cages and then removed from their home cages for more detailed observations, including measurement of grip strength and righting reflex. Data on the acute tolerance of ASOs from the present invention are presented in Table 8.

[0678] MAPT mRNA reduction in the right frontal cortical region was analyzed by qPCR as follows. Using a Quiagen TissueLyzer II, the collected mouse brain tissue (see Materials and Methods section, transgenic Tau mice) was homogenized in 10 volumes of high salt / sucrose buffer (10 mM Tris-HCl, pH 7.4, 800 mM NaCl, 10% sucrose (w / v), 1 mM EGTA) supplemented with phosphatase inhibitor cocktails 2 and 3, 1 mM PMSF (Sigma, Saint Louis, MO) and a complete protease inhibitor cocktail (without EDTA) (Roche, Indianapolis, In). The homogenate was centrifuged at 20,000 × g for 20 minutes at 4°C. The supernatant was centrifuged at 100,000 × g for 1 hour at 4°C.

[0679] For cDNA synthesis and subsequent PCR, 300 ng of RNA from the brain tissue supernatant was added to one well of a 96-well plate (Axygen, PCR-96-C-S). 7.5 μl of master mix (5 μl of 2.5 mM NTP mix and 2.5 μl of random primers per reaction) was added to each well, the plate was centrifuged at 1000 rpm and placed in a thermal cycler at 70 °C for 3 minutes. The plate was immediately cooled on ice and 4 μl of reaction master mix was added. Prior to PCR, the plate was briefly centrifuged to collect the samples at the bottom of the wells. cDNA synthesis was carried out at 42 °C for 60 minutes, at 95 °C for 10 minutes, and then held at 4 °C. The cDNA samples were diluted 1:3 with molecular biology grade water and stored at -20 °C until further use.

[0680] For PCR, each sample was run in triplicate with two probe sets (MAPT: Taqman Expression assays Hs00902193_m1; GAPDH Taqman Expression assays Hs01922876_u1). 4 μl of the previously diluted cDNA and 6 μl of master mix were added to each reaction and the plate was centrifuged. The samples were incubated at 95 °C for 20 seconds, then cycled 40 times with 95 °C incubation for 1 second and 60 °C incubation for 20 seconds.

[0681] Data was analyzed using the ΔCt method, where each sample was first normalized to GAPDH and then expressed as a percentage of the untreated control (percent inhibition). If the percent inhibition was equal to or higher than the control cells, the percent inhibition was expressed as zero inhibition.

[0682] Table 8 Acute tolerance in hTau mice and reduction of MAPT mRNA 3 days and 4 weeks after in vivo treatment

[0683]

[0684]

[0685]

[0686] NA = Not evaluated

[0687] Example 5: In vitro efficacy in human embryonic stem cell (hESC)-derived neurons.

[0688] In an alternative in vitro assay using human embryonic stem cell (hESC)-derived neurons, the selected ASOs from Example 2 were tested at three different concentrations (200 nM, 8 nM, and 0.32 nM). For comparison purposes, two prior art oligonucleotides targeting MAPT were included, namely CPM ID NO: 66_1 corresponding to ASO-001933 in WO2016 / 126995 and CPM ID NO: 67:1 corresponding to Compound No814907 in WO2018 / 064593.

[0689] Culture and ASO treatment of human embryonic stem cells (ESCs):

[0690] Neural stem cell (NSC) lines were derived from hESCs according to published procedures (Chambers et al., 2009 Nat. Biotech. 7, 275-280). Neural stem cells (NSCs) were expanded into ventralized progenitors in SFA medium over 1 week and then differentiated into neurons in BGAA medium over a 6-week period. For medium components, see the Materials and Methods section.

[0691] Cells were seeded at a density of 10,000 cells / cm 2 in N2B27+SFA medium in flasks coated with polyornithine and laminin. The medium was changed on day 4. After 7 days in N2B27+SFA medium, the cells were trypsinized and seeded as ventralized progenitors at a density of 50,000 cells / well in N2B27+BGAA medium in 96-well plates.

[0692] The medium was changed twice a week and treatment with ASO was started at the first medium change and continued for 6 weeks. Cells were then harvested as described below.

[0693] qPCR analysis:

[0694] The treated neurons were harvested as follows: the medium was removed and then 125 μl of 96 lysis buffer and 125 μl of 70% ethanol were added. RNA was purified according to the manufacturer's instructions and eluted in a final volume of 50 μl of water to give an RNA concentration of 10-20 ng / μl. Next, the RNA was diluted 10-fold in water prior to a one-step qPCR reaction.

[0695] For the one-step qPCR reaction, the qPCR-mixture (qScriptTM XLT 1-step RT-qPCR from QauntaBio (ROX) was mixed with two Taqman probes at a ratio of 10:1:1 (qPCR mixture: probe 1: probe 2) to produce the master mixture. qPCR was performed in technical replicates, and the Taqman probes were obtained from Life Technologies: MAPT_Hs00902193_m1; GAPDH 4325792 (housekeeping gene for normalization).

[0696] Then the master mixture (6 μL) and RNA (4 μL, 1 - 2 ng / μL) were mixed in a qPCR plate ( 384 well, catalog number 4309849). After sealing the plate, the plate was quickly centrifuged at 1000 g for 1 minute at room temperature and transferred to the ViiaTM 7 system (Applied Biosystems, Thermo). The following PCR conditions were used: 50 °C, 15 minutes; 95 °C, 3 minutes; 40 cycles: 95 °C for 5 seconds, then the temperature was decreased at 1.6 °C / second, then 60 °C for 45 seconds. The data was analyzed using the QuantStudioTM Real - time PCR Software. The percentage of inhibition of the ASO - treated samples was calculated relative to the control - treated samples (low values indicate a substantial reduction of MAPT). The results are shown in Table 9 and are the average of two technical replicates.

[0697] Measurement of Tau and pTau proteins in hESC neurons:

[0698] The PBS - washed cells were extracted into a buffer containing Cytobuster protein extraction reagent (Merck - Millipore #71009), 1% phosphatase inhibitor mixture 3 (Sigma #P0044), 1% protease inhibitor cocktail III (Calbiochem #539134), 1% DNase - I (Roche #4536282001) and 10 mM MgCl 2 The cell extracts were lysed by pipetting up and down and then stored at - 20 °C until use.

[0699] The total Tau level in cell extracts was measured by an in - house assay using AlphaLISA with the Tau - specific antibody 5A6 (DSHB antibody accession number: AB_528487) and the Roche in - house Tau monoclonal antibody Tau 4 / 2. The latter antibody was generated by immunizing mice with human full - length Tau (i.e., the longest human brain isoform, 441 amino acids). Tau 4 / 2 binds to a C - terminal epitope in Tau between amino acids 369 and 441. Briefly, cell extracts were diluted into AlphaLISA Hi Block assay buffer (PerkinElmer AL004C) and mixed with biotinylated 5A6 and AlphaLISa acceptor beads coated with Tau 4 / 2. After incubation for 1 hour at room temperature, streptavidin - coated donor beads were added to the mixture. After incubation for 30 minutes, the samples were measured in an Envision plate reader (ex 680 nm, em 615 nm). A standard curve was constructed using recombinant human Tau (Merck - Millipore #AG960).

[0700] The PhosphoTau (Tau - pS422) level in cell extracts was measured by AlphaLISA using an in - house Roche assay that includes the Tau - specific antibody 5A6 (DSHB antibody accession number: AB_528487) and the Tau - pS422 - specific antibody 5.6.11 (described in WO2010 / 142423 and Collin et al., Brain vol 137 P 2834 - 2846). The cell extracts were diluted into assay buffer B before the assay. Buffer B contains 25 mM HEPES pH7.4, 0.5% Triton X - 100, 0.1% Top Block (LuBio Science), 1 mg / ml Dextran500, 10% ELISA blocking reagent (Roche). A standard curve was prepared using ERK - phosphorylated Tau as follows: Recombinant human Tau was produced as described by Grueninger et al. (Neurobiology of Disease 37

[2010] pp294 - 306). Recombinant His - tagged ERK2 (produced in - house) was activated by incubation with activated MEKK1 (produced in - house). Then the activated ERK2 was incubated with Tau at a molar ratio of 1:50 in a buffer containing 2 mM ATP. Subsequently, ERK2 was removed by passing through Ni - NTA agarose (Qiagen). The degree of phosphorylation at S422 was then determined by mass spectrometry.

[0701] The results are shown in Table 9.

[0702] Table 9 MAPT reduction and Tau protein reduction in hESC-derived neurons after treatment with three different concentrations.

[0703]

[0704] Example 6: IC50 of the selected compounds from Example 5

[0705] The selection of the effective ASOs from Example 5 was tested in the same hESC-derived neuron assay together with two prior art controls (CMP ID NO 66_1 and CMP ID NO 67_1) to determine the IC50 for target mRNA reduction and Tau protein reduction.

[0706] As described in Example 5, experiments were performed using the following oligonucleotide concentrations: 1000, 200, 40, 8, 1.6, 0.32, 0.064, 0.0128, 0.00256 nM.

[0707] The IC50 values were fitted using GraphPad PRISM software. The results are shown in Table 10.

[0708] Table 10 IC50 and maximal efficacy (% of control) for MAPT and TAU proteins

[0709]

[0710] From these data, it can be seen that, on all parameters, CMP ID NO 9_103 and CMP ID NO 49_38 of the present invention are more effective and have a better IC50 than the prior art compounds, while CMP ID NO 53_1 seems to have a better maximal knockdown than the prior art compounds and an IC50 similar to CMP ID NO: 66_1.

[0711] Example 7 In vivo activity in specific brain regions of hTau mice

[0712] Four weeks after a single low-dose ICV administration, the ability of the ASOs selected from Example 5 to reduce the target in vivo in specific brain regions of humanized Tau mice (hTau mice) was tested.

[0713] The humanized Tau mice used in this example were an internal Roche hTau P301S transgenic mouse line that overexpresses human Tau (the longest human brain isoform) with a point mutation P301S on a mouse Tau background.

[0714] As described below, humanized Tau mice were administered 25 μg of ASO by intracerebroventricular (ICV) injection. CMP ID NO: 66_1 corresponds to ASO-001933 in WO2016 / 126995 and is included for comparison purposes.

[0715] In vivo ICV mouse evaluation:

[0716] Animal care:

[0717] Animals of different genders weighing 16 - 23 grams were housed in a colony room maintained at a fixed temperature (22 ± 2 °C) and humidity (55 ± 10%), and were illuminated for 12 hours per day (light started at 6:00 in the morning). All animals had free access to food and water during the study period. All mouse experiments were approved by the Danish National Committee for Animal Experimentation Ethics.

[0718] Intracerebroventricular injection:

[0719] Compounds were administered to mice via intracerebroventricular (ICV) injection. Each treatment group consisted of 6 - 8 mice of mixed genders. Before ICV dosing, the mice were weighed and anesthetized with isoflurane or propofol (30 mg per kg). During intracerebroventricular injection, a Hamilton microsyringe attached to an FEP catheter and a 23-gauge needle was fixed to a holder, adjusted to the correct piercing distance (3.9 mm), and inserted into the right ventricle after passing through the skin and skull. The nape of the neck of the mouse to be injected was held with one thumb and index finger. Gentle but steady pressure was applied to compress the head upward, piercing the skull at 1 - 2 mm to the right of the midline (mid-lateral) and 1 - 2 mm behind the eyes. A rapid bolus of 5 μl of the test compound or vehicle was injected at a preset infusion rate over 30 seconds. To avoid backflow, the mouse was held in this position for an additional 5 seconds and then carefully lowered away from the needle. This procedure did not require surgery or incision. The animals were placed under a heating lamp until they recovered from anesthesia.

[0720] At the end of the study (4 weeks), brain tissues (cortex, medulla / pons, and midbrain) were collected on dry ice for analysis of tau mRNA and protein.

[0721] Tissue homogenization:

[0722] Mouse brain tissue samples were homogenized using a Qiagen TissueLyzer II with MagNA Pure LC RNA Isolation Tissue Lyser (Roche, Indianapolis, Indiana, USA). The homogenate was incubated at room temperature for 30 minutes to allow complete lysis. The lysed homogenate was centrifuged at 13000 rpm for 3 minutes, and the supernatant was taken for analysis.

[0723] Self-organized RNA purification:

[0724] RNA was purified from 350 μl of the supernatant using the MagNA Pure 96 instrument with the kit Cellular RNA Large Volume Kit (Roche, Indianapolis, Indiana, USA). The RNA samples were normalized to 2 ng / μl with ribonuclease-free water and stored at -20 °C for later use. The MAPT mRNA levels were quantified as described in Example 5.

[0725] Measurement of Tau protein in mouse brain tissue:

[0726] Pre-weighed frozen tissue was extracted with 10 volumes (wt / vol) of extraction buffer containing 10 mM TrisCl pH 7.4, 800 mM NaCl, 1 mM EGTA, 10% sucrose, 1% phosphatase inhibitor mixture 3 (Sigma#P0044), 1% protease inhibitor cocktail III (Calbiochem#539134). A homogenate was prepared using a PreCellys tissue disruptor (20 seconds, 6500 rpm). The homogenate was then centrifuged at 10,000 × g for 20 minutes at 4 °C and the supernatant was retained for analysis.

[0727] The Tau levels in the extracts were measured by AlphaLISA using the Total Tau AlphaLISA kit (Cat. Nr. AL271C) provided by Perkin Elmer. The antibodies used in the assay were BT2 and Tau-12 provided in the kit, both of which bind to the central region of tau. The extracts were diluted into HiBlock assay buffer and then 5 μl of each sample was used for the assay. Alternatively, the assay was performed as described by the supplier.

[0728] The results of the mRNA and protein quantifications are shown in Table 11.

[0729] Table 11: In vivo efficacy in selected brain regions 4 weeks after a single ICV dose of 25 μg of ASO. MAPT mRNA (control %) is shown for four brain regions and Tau protein (control %) is shown for one brain region.

[0730]

[0731]

[0732] From these data, it can be observed that even at a relatively low concentration of 25 μg, for the compounds of the present invention, more than 20% reduction was observed in most brain regions, whereas the control compound showed near zero reduction at the target at this concentration.

[0733] Example 8 In Vivo Dose Response and Time Course in hTau Mice

[0734] The dose responses of two ASOs (CMP ID NO: 9_103 and 49_189) were evaluated using three different doses (25 μg, 50 μg, and 100 μg), and target reduction in specific brain regions was measured at 1 week and 4 weeks after administration. For comparison purposes, two prior art compounds (CMP ID NO: 66_1_103 and 67_1) were included in some of the doses in the one-week study.

[0735] This experiment was conducted essentially as described in Example 7. However, since Tau protein has a half-life of more than one week, Tau protein was not measured in the one-week dose response study. The results are shown in Tables 12 and 13.

[0736] Table 12 In vivo efficacy in selected brain regions at 1 week after a single ICV dose of 25 μg, 50 μg, or 100 μg ASO or at 4 weeks after a single ICV dose of 100 μg ASO. MAPT mRNA (as % of control) is shown for four brain regions.

[0737]

[0738]

[0739] NA = Not evaluated

[0740] Table 13 In vivo reduction of Tau protein (as % of control) at 4 weeks after a single ICV dose of 100 μg ASO.

[0741]

[0742] From the data in Tables 12 and 13, it can be seen that the compounds of the present invention perform significantly better than the prior art compounds, especially when administered at 100 μg. A MAPT reduction was also observed to be maintained at 4 weeks. In addition, after treatment with a single dose of 100 μg compound for 4 weeks, the compounds of the present invention showed a significant reduction in Tau protein.

Claims

1. An antisense oligonucleotide having a length of 10 to 30 nucleotides, the antisense oligonucleotide comprising a continuous nucleotide sequence having a length of at least 10 nucleotides, the continuous nucleotide sequence having at least 90% complementarity with a continuous nucleotide within positions 12051 to 12111, 39562 to 39593, or 72837 to 72940 of SEQ ID NO: 1, wherein the oligonucleotide is capable of reducing the expression of Tau.

2. The antisense oligonucleotide according to claim 1, wherein the continuous nucleotide sequence is at least 16 nucleotides and is 100% complementary to a continuous nucleotide within positions 12060 to 12078, 39573 to 39592, or positions 72862 to 72890 of SEQ ID NO:

1.

3. The antisense oligonucleotide according to claim 1 or 2, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 9, 6, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, and 67.

4. The antisense oligonucleotide according to any one of claims 1 to 3, wherein the continuous nucleotide sequence comprises one or more nucleosides modified at the 2'-sugar.

5. The antisense oligonucleotide according to claim 4, wherein the one or more nucleosides modified at the 2'-sugar are independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabinonucleic acid (ANA), 2'-fluoro-ANA, and LNA nucleosides.

6. The antisense oligonucleotide according to claim 4 or 5, wherein the continuous nucleotide sequence comprises 4 to 8 LNA nucleosides.

7. The antisense oligonucleotide according to claim 6, wherein: (a) the continuous nucleotide sequence comprises 8 LNA nucleosides; and / or (b) the LNA nucleosides are β-D-oxy-LNA nucleosides.

8. The antisense oligonucleotide according to any one of claims 1 to 7, wherein the oligonucleotide comprises at least one modified internucleoside bond, optionally wherein at least 80% of the internucleoside bonds within the continuous nucleotide sequence are phosphorothioate internucleoside bonds.

9. The antisense oligonucleotide according to any one of claims 1 to 8, wherein the oligonucleotide is capable of recruiting ribonuclease H.

10. The antisense oligonucleotide according to claim 9, wherein the antisense oligonucleotide or its continuous nucleotide sequence consists of a gapmer of formula 5'-F-G-F'-3' or comprises a gapmer of formula 5'-F-G-F'-3', wherein the F and F' regions independently comprise 1 to 8 nucleosides, wherein 2 to 5 are 2'-sugar modified and define the 5' and 3' ends of the F and F' regions, and G is a region between 6 and 16 nucleosides capable of recruiting ribonuclease H, such as a region comprising 6 to 16 DNA nucleosides.

11. The antisense oligonucleotide according to claim 10, wherein: (a) the 2'-sugar modified nucleosides in the F and F' regions are the same LNA nucleosides; and / or (b) all nucleotides in the G region are DNA.

12. A conjugate comprising the antisense oligonucleotide according to any one of claims 1 to 11, and at least one conjugate moiety covalently attached to the oligonucleotide.

13. The conjugate according to claim 12, wherein the conjugate moiety: (a) is a non-nucleotide moiety; (b) is an antibody or antibody fragment; (c) is an antibody or antibody fragment that facilitates delivery across the blood-brain barrier; and / or (d) is an antibody or antibody fragment that targets or has specific affinity for the transferrin receptor.

14. The conjugate according to claim 12 or 13, wherein the conjugate comprises a linker between the oligonucleotide and the conjugate moiety, optionally wherein the linker is a physiologically labile or biodegradable linker.

15. A pharmaceutically acceptable salt of the antisense oligonucleotide according to any one of claims 1 to 11 or the conjugate according to any one of claims 12 to 14.

16. A pharmaceutical composition comprising the antisense oligonucleotide according to any one of claims 1 to 11 or the conjugate according to any one of claims 12 to 14 and a pharmaceutically acceptable diluent, solvent, carrier, salts and / or adjuvants.

17. Use of the antisense oligonucleotide according to any one of claims 1 to 11 or the conjugate according to any one of claims 12 to 14 or the pharmaceutical composition according to claim 16 in the preparation of a drug for regulating Tau expression in target cells expressing Tau in vivo or in vitro.

18. Use of the antisense oligonucleotide according to any one of claims 1 to 11 or the conjugate according to any one of claims 12 to 14 or the pharmaceutical composition according to claim 16 in the preparation of a drug for the treatment or prevention of a disease.

19. Use of the antisense oligonucleotide according to claims 1 to 11 or the conjugate according to any one of claims 12 to 14 or the pharmaceutical composition according to claim 16 in the preparation of a drug for the treatment or prevention of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or FTDP-17.

20. Use of the antisense oligonucleotide, the conjugate or the pharmaceutical composition according to claim 18, wherein the disease is progressive supranuclear palsy (PSP). Use of the antisense oligonucleotide, the conjugate or the pharmaceutical composition according to claim 18, wherein the disease is Alzheimer's disease (AD).

Citation Information

Patent Citations

  • Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof

    EP2742136A1

  • Novel bicyclonucleoside and oligonucleotide analogues

    WO1998039352A1

  • Oligonucleotide analogues

    WO1999014226A2

  • Novel nucleosides and oligonucleotide analogues

    WO2000047599A1

  • L-RIBO-LNA analogues

    WO2000066604A2